Synthetic peptide studies on spike glycoprotein and 3C-like protease of the severe acute respiratory syndrome (SARS) coronavirus: perspective for SARS vaccine and drug development. by Choy, Wai Yan. & Chinese University of Hong Kong Graduate School. Division of Molecular Biotechnology.
Synthetic Peptide Studies on Spike 
Glycoprotein and 3C-like Protease of 
the Severe Acute Respiratory Syndrome 
(SARS) Coronavirus: 
Perspective for SARS Vaccine and Drug Development 
CHOY Wai Yan 
A Thesis Submitted in Partial Fulfilment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Molecular Biotechnology 
©The Chinese University of Hong Kong 
June 2005 
The Chinese University of Hong Kong holds the copyright of this thesis. Any 
person(s) intending to use a part or whole of the materials in the thesis in a 
proposed publication must seek copyright release from the Dean of the Graduate 
School. 
fu / 统 系 - 書 囷 
6 OCT 簾 1 





Supervisor: Professor NGAI Sai Ming 
(Department of Biology, The Chinese University of Hong Kong) 
Internal examiner: Professor JIANG Liwen 
(Department of Biology, The Chinese University of Hong Kong) 
Internal examiner: Professor TSUI Kwok-wing Stephen 
(Department of Biochemistry, The Chinese University of Hong Kong) 
External examiner: Professor ZHU Guang 
(Department of Biochemistry, The Hong Kong University of Science and Technology) 
i 
Statement 
Al l experimental works reported in this thesis were performed by 
the author, unless stated the otherwise. 
CHOY Wai Yan 
ii 
Abstract 
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for the degree of Master of Philosophy 
at The Chinese University of Hong Kong in June 2005 
The epidemic of severe acute respiratory syndrome (SARS) swept 
the world in early 2003. Encountering this newly emerged infectious 
disease, the world was once caught off guard and overwhelmed with 
panic-stricken atmosphere, until the novel severe acute respiratory 
syndrome coronavirus (SARS-CoV) was identified to be the etio-
logical agent of SARS. SARS-CoV contains a 30 kb RNA genome, 
with five major open reading frames encoding replicase polypro-
teins, spike (S) glycoprotein, envelope (E) protein, membrane (M) 
protein, and nucleocapsid (N) protein. A better understanding of 
some important viral proteins of SARS-CoV can shed light onto the 
iii 
development of vaccines and drugs against SARS. In this study, we 
are particularly interested in identifying the antigenic regions on S 
glycoprotein and characterizing the substrate specificity of 3C-like 
protease of SARS-CoV. 
SARS-CoV infection is mediated by S glycoprotein through re-
ceptor binding and membrane fusion between the virion and the host 
cell. Here, we focused on using synthetic peptides for developing an-
tibodies against SARS-CoV, which aimed to block viral invasion by 
eliciting an immune response specific to the native SARS-CoV S 
glycoprotein. Synthetic peptides designed according to the surface 
regions of SARS-CoV S glycoprotein were used to immunize both 
rabbits and monkeys. Antisera were analyzed by ELISA and tested 
for antibody specificity against SARS-CoV by immunofluorescent 
confocal microscopy. Four of our six synthetic peptides (S2, S3, 
S5, and S6) were capable of eliciting SARS-CoV-specific antibodies, 
which may represent some of the biologically active sequences of the 
immunogenic regions on the SARS-CoV S glycoprotein. The study 
provides novel insights for future development of synthetic peptide 
vaccines against SARS. 
iv 
Proteolytic processing of replicase polyproteins mediated by SARS-
CoV 3CLPro is essential for SARS-CoV replication and transcrip-
tion; which makes SARS-CoV a promising target for anti-
SARS drug development. Here, we presented a rapid and high-
throughput screening method to study the substrate specificity of 
SARS-CoV 3CLPro. Six target amino acid positions (P2, P3, P4, 
Pl，，P2' and P3') flanking the SARS-CoV cleavage site 
were investigated. Each batch of mixed peptide substrates with 
twenty different amino acid substitutions at the target amino acid 
position was synthesized via the 'cartridge replacement' approach, 
and was subjected to enzymatic cleavage by recombinant SARS-
CoV 3CLPro. Susceptibility of each peptide substrate to SARS-CoV 
3CLPro cleavage was monitored simultaneously by matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) mass spec-
trometer. The study generates a comprehensive overview of SARS-
CoV 3CLPro substrate specificity, which serves as the design basis 
of synthetic peptide-based SARS-CoV 3CLPro inhibitors. 
The development of effective vaccines and drugs is the ultimate 
goal in this anti-SARS combat. Our synthetic peptide-based ap-
proach is definitely a rapid initial step for providing useful informa-
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1.1 Severe acute respiratory syndrome (SARS) 
- A n overview 
1.1.1 Epidemiology of SARS 
Severe acute respiratory syndrome (SARS) was the first life threat-
ening and highly contagious viral epidemic of the 21 劝 century. The 
worldwide public health was seriously threatened by the SARS out-
break, and the World Health Organization (WHO) issued a height-
ened global health alert on March 15, 2003 about this mysterious 
pneumonia of unknown etiology, after cases identified in China's 
Guangdong Province, Hong Kong, Vietnam, Singapore and Canada. 
In retrospect, SARS was transmitted out from China's Guang-
dong Province on February 21, 2003 by an infected 65-year-old med-
ical professor who spent a single night on the ninth floor of the 
1 
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Metropole Hotel in Hong Kong, and at least 12 other secondary-
infected guests at the hotel's ninth floor thus became the seeds of 
SARS transmission around the world via international air travel 
routes. During the period from November 1, 2002 to July 31, 2003, 
there was a cumulative total of 8098 probable SARS cases with 774 
deaths reported from 29 countries (Table 1.1). 
SARS was successfully contained within 4 months since the first 
recognition in mid-March 2003, in which WHO reported the last 
human chain of transmission of SARS had been broken on July 5, 
2003 (Stadler et al, 2003). 
1.1.2 Clinical presentation of SARS 
Clinical symptoms 
SARS is an atypical form of acute pneumonia. The most common 
symptom in nearly all SARS patients was high fever with a body 
temperature of over 38®C, often associated with other symptoms 
including chills, rigors, dry cough, headache, lethargy\ malaise^, 
myalgia^, and gastrointestinal symptoms such as diarrhea (Booth 
et al, 2003; Donnelly et al, 2003; Leung et al, 2003; Peiris et a/., 
2003; Tsang et a/., 2003). These initial symptoms thus resembled 
common symptoms of other existing forms of atypical pneumonia. 
1 Abnormal drowsiness 
vague feeling of bodily discomfort 
^Muscular pain or tenderness 
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Table 1.1: The number of reported SARS cases from different countries during 
the period from November 1，2002 to July 31，2003. 
^ 1 Cumulative no. 
Country , , 、 No. of deaths 
of case(s) 
Australia 6 0 
Canada 251 43 
China 5327 349 
France 7 1 
Germany 9 0 
Hong Kong 1755 299 
India 3 0 
Indonesia 2 0 
Italy 4 0 
Kuwait 1 0 
Macao 1 0 
Malaysia 5 2 
Mongolia 9 0 
New Zealand 1 0 
Philippines 14 2 
Republic of Ireland 1 0 
Republic of Korea 3 0 
Romania 1 0 
Russian Federation 1 0 
Singapore 238 33 
South Africa 1 1 
Spain 1 0 
Sweden 5 0 
Switzerland 1 0 
Taiwan 346 37 
Thailand 9 2 
United Kingdom 4 0 
United States 29 0 
Vietnam 63 5 
Total: 8098 Total: 774 
(Modified from http://www.sarsreference.com/sarsref/epidem.htm) 
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Laboratory findings 
Characteristic changes in peripheral blood counts which included 
leucopenia^ (in particular lymphopenia^) and thrombocytopenia^ 
were common in SARS patients (Ksiazek et al, 2003; Kuiken et a/., 
2003; Poutanen et a/., 2003). Remarkable reduction in both the 
CD47 and CD8^ T cell counts was noted during the early phase 
of illness (Cui et al, 2003; Wong et a/., 20036). Other common 
laboratory findings in SARS patients included elevated levels of lac-
tate dehydrogenase (LDH), C-reactive protein^, aspartate or alanine 
aminotransferases, and creatine phosphokinase (Booth et al, 2003; 
Lee et al., 2003; Peiris et aL, 2003; Poutanen et a/., 2003; Tsang 
et al。2003). A prolonged activated partial-thromboplastin^^ time 
and elevated D-dimer^^ level were also noted in a substantial number 
of patients (Lee et al., 2003). 
Chest radiography and high-resolution computed tomography findings 
Chest radiography and high-resolution computed tomographic lung 
scan played an important role in the early diagnosis of SARS. At the 
4An abnormal reduction of the white blood cell count 
5 An abnormal reduction in the number of lymphocytes in the blood 
®An abnormal reduction in the number of platelets in the blood 
glycoprotein predominantly found on the surface of helper T cells 
8 A glycoprotein predominantly found on the surface of cytotoxic T cells 
9A globulin that appears in the blood in certain acute inflammatory conditions 
10A protease that converts prothrombin to thrombin in the early stages of blood clotting 
11A blood test for the detection of thrombosis 
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onset of fever, 70-80% of the SARS patients had abnormal chest ra-
diographs on presentation (Booth et al., 2003; Wong et al., 2003a). 
Lung infiltrates were often shown in early chest radiography, and 
patchy ground-glass opacification of the lung parenchyma was de-
tected readily by computed tomographic scans (Wong et al., 2003a). 
Progression of lung infiltrates with the increase in air-space opac-
ities and multiple patchy consolidations of both lungs were shown 
for SARS patients with clinical deterioration, which required intu-
bation and mechanical ventilation (Tsang et al., 2003; Tsui et al, 
2003; Wong et al., 2003a). 
1.1.3 Diagnostic tests of SARS 
Laboratory confirmation of SARS was based on the virus isolation, 
viral RNA detection, or antibody detection of the etiological severe 
acute respiratory syndrome coronavirus (SARS-CoV). 
The presence of SARS-CoV can be detected by inoculating SARS-
permissive cells such as Vero cells with clinical specimens^^ to prop-
agate SARS-CoV in vitro. Reverse transcription-polymerase chain 
reaction (RT-PCR) and nucleic acid sequence-based amplification 
(NASBA) could be used to detect SARS-CoV-specific RNA in clini-
cal specimens. Conventional RT-PCR assays require post amplifica-
tion product processing such as gel electrophoresis and southern blot 
i^Blood，serum, sputum, oropharyngeal materials, nasopharyngeal materials or stool 
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hybridization, that are time-consuming and require multiple han-
dling steps of the PGR products (Drosten et al, 2003; Peiris et al, 
2003; Yam et al, 2003). On the other hand, the real-time moni-
toring of accumulating amplicon by real-time PGR or NASBA en-
ables quantitative and highly sensitive measurement, which is more 
preferable for the detection of SARS-CoV-specific RNA (Mackay 
et a/., 2002; Emery et al, 2004). 
Antibodies that are produced in response to SARS infection can 
be detected by enzyme-linked immunosorbent assay (ELISA), im-
munofluorescent microscopy, and neutralization test. ELISA and 
immunofiuorescent microscopy detect a mixture of immunoglobu-
lin M (IgM) and immunoglobulin G (IgG) antibodies in the SARS 
patient sera that specifically bind to the recombinant SARS-CoV 
proteins and SARS-CoV-infected cells fixed on a microscope slide, 
respectively (Ksiazek et a/., 2003; Shi et al, 2003; Wu et a/., 20046). 
Neutralization test is regarded as the most specific and the best cor-
relate of immunity among all the serological tests for SARS-CoV, 
since it detects and quantifies SARS-CoV-specific immunoglobulins 
in the SARS patient sera by measuring their ability to neutralize the 
infectivity of SARS-CoV on cell culture (Wu et al, 20046). Since 
all these diagnostic tests for SARS-CoV available so far have limita-
tions, special caution is required for result interpretations, in order 
to avoid false sense of security based on false negative test results. 
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1.1.4 Treatment of SARS 
To date, there is no specific drug formulation against SARS-CoV in-
fection. During the SARS outbreak in 2003, the mainstream thera-
peutic treatment of SARS included broad-spectrum antibiotics, an-
tiviral agents, and immunomodulatory therapy. Suspected cases of 
SARS were initially prescribed with broad-spectrum anti-bacterial 
agents against typical bacterial causes of acute community-acquired 
or n o s o c o m i a l i 3 pneumonia. These broad-spectrum antibiotics in-
cluded fluoroquinolones, cephalosporins and macrolide (Groneberg 
et al., 2005). The antibiotic therapy could be withdrawn once SAR-
CoV was identified in the SARS suspected case. Antiviral therapies 
included the administration of ribavirin^^, oseltamivir phosphate^^, 
lopinavir-ritonavir co-formulation^®, and human interferons (Booth 
et al, 2003; Cinatl et al, 2003; Lee et al., 2003; Peiris et al。 
2003; Poutanen et aL, 2003; Tsang et al, 2003; Tsui et al, 2003; 
Groneberg et a/., 2005). Also, corticosteroids were widely used for 
immunomodulatory therapy to reduce immune hyperactivity due 
to cytokine dysregulation and induction of inflammatory mediators 
with diffuse alveolar damage (Ho et al, 2003; Nicholls et al., 2003). 
^^Originating in the hospital 
14 a nucleoside analog with broad-spectrum antiviral activity 
15 A neuraminidase inhibitor for the treatment of both influenza A and B viruses 
16a protease inhibitor preparation used to treat HIV 
CHAPTER 1. INTRODUCTION 8 
1.2 Severe acute respiratory syndrome coron-
avirus (SARS-CoV) 
1.2.1 The etiological agent of SARS 
During the initial outbreak of SARS in early March 2003, iden-
tification of the causative agent of the newly emerging infectious 
SARS was once an urgent and challenging task faced by the re-
searchers worldwide. On March 17，2003, WHO called upon 11 
leading laboratories around the world to setup a multicenter re-
search network for identifying the unknown etiology of SARS. In 
the beginning of the investigations, infectious pathogens such as 
Chlamydia (Drosten et aL, 2003), rhinoviruses (Ksiazek et al, 2003) 
and paramyxoviruses (Poutanen et al., 2003) that cause interstitial 
pneumoniai7 were identified in some SARS patients, and considered 
as potential causative agents of SARS. Nonetheless, the presence of 
these pathogens could not be confirmed in all SARS cases (Drosten 
et al, 2003; Ksiazek et al., 2003; Peiris et a/., 2003). 
By unprecedented global collaborative efforts, the causative agent 
of SARS was finally identified to be a novel human coronavirus 
known as severe acute respiratory syndrome coronavirus (SARS-
CoV) in late March 2003. Different laboratories were able to iso-
late SARS-CoV from Vero E6 cells and fetal rhesus kidney cells 
i^Chronic lung disease that affects the interstitial tissue of lung 
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(FRhK-4) that were inoculated with clinical specimens^^ collected 
from SARS patients (Drosten et al, 2003; Ksiazek et al, 2003; 
Peiris et al., 2003). Electron-microscopic examination of culture su-
pernatants revealed characteristic ultrastructural features of coro-
naviruses (Ksiazek et al, 2003; Peiris et al., 2003). Furthermore, 
monkeys infected with the isolated virus showed similar symptoms 
to human cases of SARS (Fouchier et al” 2003). Hence, after con-
firming the casual relationship between the virus and SARS ac-
cording to the Koch's postulates (Fouchier et al, 2003), WHO an-
nounced that this novel, previously unknown coronavirus, SARS-
CoV, as the etiological agent of SARS. 
1.2.2 The coronaviruses 
Coronavirus is a genus of animal virus which belongs to the family 
Coronaviridae. Coronaviruses are large, enveloped, single-stranded 
positive sense RNA viruses that replicate in the cytoplasm of animal 
host cells (Siddell et al., 1983). The genomic size of coronaviruses 
ranges from approximately 27 to 32 kb. The size of each coron-
avirus particle is about 100 to 140 nm in diameter. Most of the 
coronaviruses show distinct crown (，corona，in Latin) surface ap-
pearance which is attributed to the 20 nm projections of spike (S) 
glycoprotein from the virion surface. 
i8Sputum’ oropharyngeal and nasopharyngeal materials 
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Previously, coronaviruses have been divided into three groups 
based on serological cross-reactivity and genomic sequence homol-
ogy (Siddell et al., 1983; Gonzalez et al, 2003). Mammalian viruses 
are found in groups 1 and 2, and avian viruses are found only in 
group 3. Group 1 includes canine coronavirus (CCV), feline coro-
navirus (FIPV), human coronavirus 229E (HCoV-229E), porcine 
epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus 
(TGEV)，and human coronavirus-NL63 (HCoV-NL63). Group 2 in-
cludes bovine coronavirus (BCV), human coronavirus OC43 (HCoV-
OC43), mouse hepatitis virus (MHV) and rat coronavirus (RCV). 
Group 3 includes avian infectious bronchitis virus (AIBV) and turkey 
coronavirus (TCoV) (Siddell et al, 1983; Gonzalez et al., 2003). 
In the past，human coronaviruses found in both group 1 (HCoV-
229E) and group 2 (HCoV-OC43) were associated only wi th mild 
upper respiratory tract diseases (Makela et al., 1998), whereas the 
novel SARS-CoV appears to be the first human coronavirus respon-
sible for severe disease in humans. Phylogenetic analysis indicates 
that SARS-CoV does not belong to any of the above three groups, 
which contain all other known coronaviruses, including the human 
coronaviruses. This suggests that SARS-CoV did not arise by re-
combination or mutation of the known coronaviruses; hence, the 
novel SARS-CoV defines a distinct fourth group of coronaviruses 
(Marra et a/., 2003; Rota et al, 2003). 
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1.2.3 Genome of SARS-CoV 
SARS-CoV contains a polyadenylated RNA genome of approxi-
mately 30 kb, which is organized into 13 to 15 open reading frames 
(ORFs) (Marra et al, 2003; Rota et al, 2003; Thiel et al, 2003). 
Its overall genome organization is typical of other coronaviruses: 5' 
-replicase - spike (S) - envelope (E) - membrane (M) - nucleocapsid 
(N) - 3, (Figure 1.1). 
0 5 10 15 20 25 30 kb 1 I I I I I I 
Replicase ORMa M N 
^ H I ^ ^ m ^ H B I 3a 口7b8a_ 
• DD D9B ORFs 
^ ^ m ^ ^ m w m m D D D 
Replicase ORFIb S 3b 7a8b 
Figure 1.1: Genome organization of SARS-CoV. 
The organization of SARS-CoV genome: 5’ - replicase - spike (S) - envelope (E)-
membrane (M) - nucleocapsid (N) - 3，(Modified from Thiel et al., 2003). 
The overlapping replicase ORFla and ORFlb comprises two-
thirds of the SARS-CoV genome, which are located at the 5’ region 
downstream of the predicted RNA leader sequence (nucleotides 1-
71) and an untranslated region (UTR) spanning 192 nucleotides. 
The replicase genes encode a number of proteins required for vi-
ral replication and transcription via proteolytic cleavage of a large 
polyprotein; more details on replicase polyproteins are discussed in 
section 1.4. 
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Structural proteins S, E, M and N are encoded by four ORFs 
located at the 3’ region of the SARS-CoV genome, in which they are 
crucial to host cell entry, virion morphogenesis and release (Marra 
et al., 2003) (Figure 1.2). 
# # 0 ^ ^ S g l y c o p r o t e i n 
R 从 M p r o t e i n 
N P r o t e i n ^ ^ ^ ^ E p r o t e i n 
Figure 1.2: Structural proteins of SARS-CoV. 
Structural proteins of SARS-CoV include spike (S) glycoprotein, envelope (E) protein, 
membrane (M) protein and nucleocapsid (N) protein. (Modified from Groneberg et al., 
2005). 
The nucleocapsid (N) protein and the membrane (M) protein in-
teract to form a spherical core, whereas the spike (S) glycoprotein, 
and the envelope (E) protein constitute the viral envelope (Marra 
et al” 2003; Rota et al, 2003; Thiel et al, 2003). During the as-
sembly of viral particles, the helical nucleocapsid is formed by the 
binding of N protein to a defined packaging signal on viral RNA. 
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Interactions between the E protein, M protein and the nucleocap-
sid trigger the budding event of the virion; and S glycoprotein is 
incorporated into the viral envelope which mediates the release of 
mature viral particles (Garoff et al, 1998). 
S glycoprotein plays an important role in binding to host-specific 
receptors and facilitating viral entry and fusion; more details on S 
glycoprotein are discussed in section 2.1 (Lai and Cavanagh, 1997; 
Gallagher and Buchmeier, 2001; Bosch et al, 2003; Holmes, 2003; 
Hofmann and Pohlmann, 2004). N protein is responsible for provid-
ing nuclear-import signals, interfering cellular process, viral repli-
cation and RNA packaging (Kuo and Masters, 2002; Hiscox et al, 
2001). Previous studies indicated that the N protein from other 
strains of coronaviruses can cause massive hepatocellular necrosis^^ 
in the host body (Ning et al, 2003). E protein is involved in virion 
envelope formation and the generation of virus-like particles when 
coexpressing wi th M protein (Vennema et al., 1996), and also the 
induction of apoptosis (An et al., 1999). 
In addition to these proteins, the genome of SARS-CoV also con-
tains several accessory genes that encode a number of non-structural 
proteins (Marra et al, 2003; Rota et al, 2003). 
i9The localized death of living cells 
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1.3 Spike (S) glycoprotein of SARS-CoV 
The distinct and characteristic crown appearance on the surface of 
the SARS-CoV is attributed to the membrane projections of the 
spike (S) glycoprotein from the viral envelope (Schmidt et al., 1987; 
Ksiazek et al., 2003). The open reading frame encoding for S gly-
coprotein of SARS-CoV is 3768 nucleotides in length, comprising 
12.67% of the total genome. The S glycoprotein is the largest struc-
tural viral protein in SARS-CoV and it is composed of 1255 amino 
acids with an estimated molecular mass of 139.12 kDa (Choy et al., 
2004). 
There are 23 potential N-linked glycosylations and 69 potential 
sites of phosphorylation, including 37 serine, 15 threonine, and 17 
tyrosine residues (Choy et al., 2004) as predicted by sequence analy-
sis. The S glycoprotein of SARS-CoV demonstrates a low sequence 
similarity level of 20% to 27% pair wise amino acid identity with 
the previous identified S glycoproteins of other known coronaviruses 
(Rota et al, 2003; Choy et al, 2004). The SARS-CoV S glycopro-
tein is a type I intergral membrane glycoprotein that consists of a 
leader (residues 1-14), an ectodomain (residues 15-1190), a trans-
membrane domain (residues 1191-1227), and a short intracellular 
tai l (residues 1227-1255) rich in conserved cysteine residues (Rota 
et al., 2003). 
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1.3.1 Functions of SARS-CoV S glycoprotein 
The S glycoprotein of SARS-CoV is a typical type I viral fusion 
protein that plays a significant role in mediating the viral binding 
to species-specific host cell receptors, which further triggers a fusion 
event between the viral envelope and a cellular membrane to facili-
tate viral entry (Lai and Cavanagh, 1997; Gallagher and Buchmeier, 
2001; Bosch et al, 2003; Holmes, 2003; Hofmann and Pohlmann, 
2004). Thus, it serves as the major inducer of neutralizing antibod-
ies. Besides, the SARS-CoV S glycoprotein is also responsible for 
SARS-CoV pathogenesis, virulence and host cell tropism (Leparc-
Goffart et al., 1998; Sanchez et al., 1999; Phillips et al., 2002). 
In fact, the S glycoprotein of SARS-CoV is composed of two 
subunits: the surface SI subunit and the transmembrane S2 sub-
unit. In contrast to the S glycoproteins of other coronaviruses such 
as mouse hepatitis virus (MHV), bovine coronavirus (BCV), avian 
infectious bronchitis virus (AIBV) and human coronavirus OC43 
(HCoV-〇C43) that undergo proteolytic cleavage into the two non-
covalently associated SI and S2 subunits (Stern and Sefton, 1982; 
Sturman and Holmes, 1984; Prana et al” 1985; Jackwood et al., 
2001), there is no typical cleavage motif being identified in the 
SARS-CoV S glycoprotein (Rota et al。2003; He et al., 2005). On 
the other hand, this issue remains controversial as other studies have 
demonstrated the cleavage of the SARS-CoV S glycoprotein in virus 
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infected cell lysate (Wu et al, 2004c). Nevertheless, the SI and S2 
subunits of the SARS-CoV S glycoprotein can be predicted in silico 
via sequence alignment with the SI and S2 subunits of the cleaved 
S glycoproteins of other coronaviruses, in which they are predicted 
to be localized at the regions of amino acid residues 17-680 and 
681-1255，respectively (Rota et al, 2003; Spiga et aL, 2003). The 
SI subunit harbors the receptor-binding domain which defines the 
host range of the virus (Cavanagh et al, 1986; Taguchi, 1995), and 
it is suggested to be the major antigenic determinants for eliciting 
immune response in the hosts (Cavanagh et al, 1986; Correa et al, 
1990; Delmas et al., 1990; Kapczynski et al., 2003). 
The S2 subunit is the stem region of the S glycoprotein that con-
tains a putative fusion peptide and two highly conserved heptad re-
peats (HR l and HR2), which are responsible for the fusion between 
viral and cellular membranes (Bosch et al., 2003). During the virus 
fusion process, the H R l region at the amino terminus and HR2 re-
gion at the carboxyl terminus undergo a series of conformational 
changes, from the pre-fusion state to the pre-hairpin intermediate 
state, and then to the final post-fusion hairpin state (Eckert and 
Kim, 2001). Previous studies demonstrated that three H R l helices 
interact wi th three HR2 helices in an anti-parallel manner to form 
a stable six-helix coiled-coil bundle structure (Bosch et al., 2004; 
Ingallinella et al., 2004; Liu et al., 2004; Tripet et al, 2004; Xu 
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et aL, 20046)，which resembles the fusion-active core of the mouse 
hepatitis virus (MHV) S glycoprotein (Xu et al., 2004a) and human 
immunodeficiency virus type 1 (HIV-1) gp41 from the envelope gly-
coprotein (Chan et aL, 1997). This trimer of hairpins fusion core 
facilitates the juxtaposition of the viral and cellular membranes into 
close proximity, destabilizes the membrane lipid bilayers, which ul-
timately leads to the fusion and release of the viral nucleocapsid 
into the host cell (Tripet et al。2004). 
1.3.2 Receptors for S glycoprotein of SARS-CoV 
The coronavirus S glycoprotein mediates viral infection of receptor-
expressing target cells (Lai and Cavanagh, 1997; Gallagher and 
Buchmeier, 2001; Bosch et al, 2003; Holmes, 2003; Hofmann and 
Pohlmann, 2004), thus the identification of receptors for S glycopro-
teins can provide insights into the molecular mechanisms of coron-
avirus entry, pathogenesis and host cell tropism. 
Although several S glycoprotein receptors were previously iden-
tified for other coronaviruses, such as the aminopeptidase N (APN) 
glycoproteins for human coronavirus 229E (HCoV-229E) and murine 
carcinoembryonic antigen cell adhesion molecule 1 (CEACAMl) for 
mouse hepatitis virus (MHV) (Yeager et al, 1992; Wentworth and 
Holmes, 2001; Marra et al., 2003); SARS-CoV S glycoprotein does 
not utilize any of these receptors, which is accounted by its low 
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sequence similarity with other coronavirus S glycoproteins (Marra 
et al, 2003; Rota et a/., 2003). 
Angiotensin-converting enzyme 2 (ACE2) 
By using the immunoprecipitation and mass spectrometry approach, 
angiotensin-converting enzyme 2 (ACE2) (Donoghue et al, 2000; 
Tipnis et al, 2000) was first identified by Li's group to be a func-
tional receptor for the S glycoprotein of SARS-CoV (Li et al, 2003); 
which is consistent with the independent finding of Wang's group 
using the flow cytometry and expression cloning approach (Wang 
et al., 2004), ACE2 is a type I integral membrane protein that is 
composed of 805 amino acids (Donoghue et al., 2000; Tipnis et al., 
2000). I t is a zinc-containing carboxypeptidase that converts an-
giotensin I to angiotensin I I in the renin-angiotensin system, which 
plays an essential role in the regulation of heart function by main-
taining blood pressure homeostasis (Crackower et al, 2002; Eriksson 
et a/., 2002). 
A 193-amino-acid receptor binding domain (RBD) of the SARS-
CoV S glycoprotein is demonstrated to bind ACE2 with high affinity 
and efficiently block S glycoprotein-mediated SARS-CoV infection 
(Wong et al., 2004). The high expression level of ACE2 in lung, 
kidney, heart and the gastrointestinal systems (Harmer et al., 2002; 
Komatsu et al., 2002) can account for the isolation of SARS-CoV 
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from each of these target tissues in SARS-CoV infected humans and 
animals. Several lines of evidence suggested ACE2 as the primary 
physiologically relevant receptor for SARS-CoV infection, and may 
play a critical role in SARS-CoV replication in the infected host 
cells (Li et a/., 2003; Hamming et al, 2004; Nie et al, 2004). 
CD209L 
In addition to the functional receptor ACE2, a different human cel-
lular glycoprotein, CD209L (also called L-SIGN, DC-SIGNR and 
DC-SIGN2), was claimed to be an alternative receptor for the S 
glycoprotein of SARS-CoV (Jeffers et al., 2004). I t is demonstrated 
that human CD209L interacts specifically with purified recombinant 
SARS-CoV S glycoprotein (Jeffers et al” 2004). Although CD209L 
was shown to enhance S glycoprotein-mediated SARS-CoV infection 
of ACE2-expressing permissive cells in trans, CD209L expression 
does not facilitate SARS-CoV S-driven infection of non-permissive 
cells in the absence of ACE2 (Marzi et al., 2004; Yang et al” 2004a). 
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1.4 3C-like protease (3CLPr。) of SARS-CoV 
1.4.1 Extensive proteolytic processing of SARS-CoV repli-
case polyproteins 
Common to other coronaviruses, SARS-CoV replicates in the cy-
toplasm of the infected host cells. The 5'-proximal overlapping 
replicase ORFla and ORFlb are translated into two large repli-
case polyproteins ppla and pplab (Marra et al, 2003; Rota et al, 
2003). I t is predicted that the expression of ORFlb-encoded re-
gion of pplab involves a translation read-through by a -1 ribosomal 
frameshift mechanism upstream of the ORFla translation termina-
tion codon (Thiel et al, 2003). The 486-kDa polyprotein ppla con-
tains a papain-like protease (PL2P^°), a 3C-like protease (3CLPro), 
two putative membrane proteins M P l (nsp4) and MP2 (nsp6), and 
several proteins of unknown function. The 790-kDa polyprotein 
pplab contains a helicase domain (nspl3) with ATPase and DNA 
duplex unwinding activities, a RNA polymerase (nspl2), an exonu-
clease (nspl4), an endoribonuclease (nspl5), and a methyltrans-
ferase (nspl6) (Schmidt-Mende et al, 2001). 
The ppla and pplab polyproteins undergo extensive processing 
by viral proteases to yield 16 nonstructural protein products (nspl 
to nspl6) that assemble into a membrane-bound viral replication 
complex, for mediating both genome replication and transcription 
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of subgenomic mRNAs (Ziebuhr et al, 2000; Thiel et al。2003). 
SARS-CoV PL2Pro cleaves the N-proximal region of pp la and pplab 
at three sites, whereas SARS-CoV cleaves the central and C-
proximal polyproteins regions at 11 conserved sites (Ziebuhr et al, 
2000; Thiel et al., 2003). 
1.4.2 SARS-CoV 3CLPr° 
The 33.8-kDa SARS-CoV which is also known as the SARS-
CoV main protease (MPr。), is being considered extensively as an 
attractive and promising target for anti-SARS drug design, owing 
to its important biological role in the viral life cycle (Anand et al., 
2003). The reported X-ray crystal structures of the SARS-CoV 
3QLpro allow the investigation of possible interactions of SARS-CoV 
3QLpro with its substrates, which contribute to the development of 
specific protease inhibitors as potential anti-SARS drugs (Anand 
et al., 2003; Yang et a/., 2003) (Figure 1.3). 
SARS-CoV 3CLPro is a homodimer with two perpendicularly-
arranged subunits. Each monomer of SARS-CoV comprises 
three structural domains including the catalytic domain I (residues 
8-101) and domain I I (residues 102-184) that form the N-terminal 
chymotrypsin fold, and the unique C-terminal extra a-helical do-
main I I I (residues 201-301) that is important for regulating the 
activity and specificity of SARS-CoV by controlling the 
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HUHBI^ I 
Figure 1.3: Dimer structure of SARS-CoV 3CLP^°. 
SARS-CoV 3CLPro is a homodimer, in which each monomer comprises structural do-
mains I，II，and III. (Modified from Yang et al., 2003). 
dimerization of the enzyme (Shi et al., 2004). Although SARS-
CoV 3CLPr。resembles a chymotrypsin-like two/^-barrel fold, it em-
ploys the active nucleophile Cysl45 and the acid-base catalyst His41 
at the catalytic dyad instead of the classical Ser-His-Asp catalytic 
triad, by lacking an acidic residue (Thiel et al., 2003). 
1.4.3 Substrate specificity of SARS-CoV 
Based on sequence analysis (Figure 4.1), it is demonstrated that 
SARS-CoV 3CLPr。cleaves the replicase polyproteins at no less than 
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11 conserved sites, in which the substrate specificity involves pref-
erentially the Leu-Gln 丄 sequence in P2 and P I positions^® at the 
cleavage site, respectively (Ziebuhr et al, 2000; Hegyi and Ziebuhr, 
2002; Anand et al, 2003). Previous studies on the 3CLPr。of other 
coronaviruses suggested the conservation of the P I (Gin), P2 (Leu, 
lie, Val, Phe, Met), P4 (Ser, Thr, Val, Pro, Ala), P1' (Ser, Ala, Gly, 
Asn, Cys) positions at the cleavage site in determining the SCLPr。 
substrate specificity (Ziebuhr et aL, 2000). In addition to the in 
silico sequence analyses of the SARS-CoV ，wet-lab, exper-
iments are necessary to provide a more comprehensive and valid 
interpretation on the substrate specificity preference of SARS-CoV 
3CLPro，for a better understanding on the specific enzyme-substrate 
binding mechanism during the SARS-CoV 3CLPro proteolytic cleav-
age process. 
20According to the naming system suggested by Berger and Schechter (Berger and Schechter, 
1970), the position (P) on the substrate is counted from the point of cleavage, i.e. P I is the 
position just before the cleavage site 丄,with P I , P2, . . . etc. located at N-terminal to the 
cleavage site; and P1', P2', . . . etc. located at C-terminal to the cleavage site. 
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1.5 Combating SARS - Vaccine and drug devel-
opment 
1.5.1 Vaccine development against SARS 
The development of safe and effective vaccines and drugs is the ulti-
mate goal in this combat against SARS. Currently, mainstream anti-
SARS vaccine candidates include inactivated SARS-CoV vaccines, 
DNA vaccines, and attenuated viral-vectored vaccines; nonetheless, 
only the inactivated SARS-CoV vaccines are tested in clinical trial 
(He et al., 2004; Marshall and Enserink, 2004; Zhou et al., 2005). 
Inactivated SARS-CoV vaccines were prepared by treating SARS-
CoV infected Vero cell lysates with /3-propiolactone or formalde-
hyde; to date, these inactivated SARS-CoV vaccines have been eval-
uated for immunogenicity, safety and protectivity in mice, rabbits 
and rhesus monkeys (He et al, 2004; Marshall and Enserink, 2004; 
Zhou et al., 2005). Besides, DNA vaccines are studied extensively 
as potential SARS vaccine candidates. DNA plasmids encoding the 
SARS-CoV spike (S) glycoprotein or nucleocapsid (N) protein were 
synthesized using human-preferred codon，so as to optimize gene ex-
pression and to minimize the chance of recombination with endoge-
nous cor onavir uses. Neutralizing antibody responses, CD4 and CDS 
T cells-mediated responses, and protective immunity were induced 
in mice that were immunized with DNA plasmids (Kim et al., 2004; 
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Yang et al., 20046). In addition, attenuated viral-vectored vaccines 
such as the highly attenuated modified vaccinia virus Ankara (MVA) 
and attenuated parainfluenza virus (BHPIV3) containing the gene 
encoding the codon-optimized SARS-CoV S glycoprotein, were used 
to immunize mice and African green monkeys, which demonstrated 
reduction of SARS-CoV replication and complete protection against 
shedding of SARS-CoV, respectively (Bisht et al., 2004; Bukreyev 
et al, 2004). 
1.5.2 Drug development against SARS 
Owing to the important biological role of SARS-CoV 3CLPr° ^^ 
the viral life cycle, it is being considered extensively as an attrac-
tive and promising target for anti-SARS drug design (Anand et al., 
2003). Efforts in screening different potential inhibitors of SARS-
CoV 3CLPr° are underway worldwide. 
To date, a number of potential candidates of SARS-CoV 
inhibitors were identified from different compound and drug libraries, 
such as antiviral drugs^^ already in human clinical use, Food and 
Drug Administration (FDA) approved compounds, National Cancer 
Institute (NCI) small molecules database, MDL Drug Data Report 
(MDDR) database, MDL Available Chemicals Directory (ACD) 
database, LeadQuest database, Maybridge database, International 
21 Drugs for treating other coronaviruses and HIV-1 
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Species Information System (ISIS) database, MicroSource Gene-
sis Plus Collection database, Chinese Medicine Database (TCMD), 
Marine Natural Products Database (MNPD), . . . etc (Hsu et al., 
2004; Kao et al., 2004; Rajnarayanan et a/., 2004; Wu et al。2004a; 
Yamamoto et al., 2004; Liu and Zhou, 2005). Most of these SARS-
CoV inhibitor candidates were proposed using in silico molec-
ular modeling and virtual screening approaches, in which only a few 
of them were experimentally tested for inhibitory activity. 
Nelfinavir, a widely used human immunodeficiency virus type 1 
(HIV-1) protease inhibitor, was demonstrated to strongly inhibit 
SARS-CoV replication (Yamamoto et al, 2004). Two calpain^^ 
inhibitors also served as potent inhibitors of SARS-CoV replica-
t ion (Barnard et al, 2004). In addition, bifunctional aryl boronic 
compounds (specifically targeting the cluster of serine residues^^ 
near the SARS-CoV active site) (Bacha et al., 2004), metal-
conjugated compounds (e.g. l-hydroxypyridine-2-thione zinc) (Hsu 
et al., 2004)，keto-glutamine analogs (with a phthalhydrazido group 
at the a-position) (Jain et al., 2004), and several synthetic pep-
tide substrates (Yang et al., 2003) were shown to be effective at 
inhibit ing SARS-CoV 3CLP^°. 
^^Calcium-activated cytoplasmic cysteine proteases 
23Serl39, Serl44, and Serl47 
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1.6 Project objectives of this thesis 
In this project, we mainly focused on using synthetic peptide-based 
approach to study two of the SARS-CoV proteins, including SARS-
CoV S glycoprotein and SARS-CoV 
1.6.1 Synthetic Peptide Studies on SARS-CoV S glyco-
protein 
The potential receptor-binding site of SARS-CoV should lie within 
the surface region of S glycoprotein, and it would be a good tar-
get for the development of synthetic peptide-based vaccines against 
SARS-CoV. To date, there is no specific treatment for SARS, and 
the control of SARS-CoV infection by vaccination is not yet avail-
able. In this study, we focused on the use of biologically active 
synthetic peptides for viral protein neutralization, which aimed to 
block the viral invasion by eliciting an immune response that could 
specifically recognize and neutralize the S glycoprotein of SARS-
CoV. Potential surface regions of SARS-CoV S glycoprotein served 
as the design basis of our peptides, which can be predicted in silico 
by sequence analyses on the secondary structure, hydrophobicity 
and posttranslational modifications. Synthetic peptides were used 
to immunize both rabbits and monkeys. Antisera were then ana-
lyzed by ELISA and tested for antibody specificity against SARS-
CoV by immunofluorescent confocal microscopy. Our study can 
CHAPTER 1. INTRODUCTION 28 
also provide novel insights into future vaccine development against 
SARS-CoV by the synthetic peptide-based approach and help to 
achieve better understanding of SARS to allow better preparation 
for possible recurrences of SARS. 
1.6.2 Synthetic Peptide Studies on SARS-CoV 
A better understanding of the specific enzyme-substrate binding 
mechanism during the SARS-CoV 3CLPr° proteolytic cleavage pro-
cess is required for the rational design of an effective protease in-
hibitor with strong binding affinity to SARS-CoV TO screen 
the substrate specificity of SARS-CoV 3CLP^° in a rapid and high-
throughput manner in contrast to the traditional tedious proce-
dures, we applied the matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometric analysis in com-
bination with the 'cartridge replacement' solid-phase peptide syn-
thesis approach to investigate the biological significance of amino 
acid residues in the P2, P3, P4, P1', P2' and P3' positions that 
are flanking the conserved Gin residue in P I position at the SARS-
CoV cleavage site. Owing to the sensitivity of MALDI-TOF 
mass spectrometer, the protease cleavage reaction of a mixture of 
different peptide substrates can be monitored simultaneously to gen-
erate comprehensive data on the substrate specificity of SARS-CoV 
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3CLPro. Therefore, all the twenty possibilities of amino acid sub-
stitutions in a particular position of the peptide substrate can be 
easily investigated in the same reaction. 
Our study can provide insights into the molecular mechanism 
of SARS-CoV 3CLPr° cleavage process and reveal the feasibility of 
developing synthetic peptide-based protease inhibitors as potential 
drugs against SARS-CoV and other coronavirus infections. Further-
more, the rapid approach we described here is widely applicable for 
monitoring the cleavage activities of other proteases, such as allow-
ing the rapid screening of potential protease inhibitors of the human 
immunodeficiency virus type 1 (HIV-1) as the basis of drug develop-
ment. In addition, automations are highly compatible and feasible 
with our experimental procedures to cope with the increasing de-
mand of high-throughput analyses in proteomic research. 
寺 End of chapter. 
Chapter 2 
Materials and Methods 
2.1 Synthetic peptide studies on SARS-CoV S 
glycoprotein 
2.1.1 Bioinformatics analyses of SARS-CoV S glycopro-
tein 
The genome sequence of SARS-CoV used for peptide design in this 
study was based on the SARS-CoV CUHK-SulO complete genome 
sequence [GenBank accession no. AY282752] downloaded from Gen-
Banki. xhe correct open reading frame (ORF) of SARS-CoV spike 
(S) glycoprotein was determined by ORF Finder^. Predicted amino 
acid sequence of SARS-CoV S glycoprotein was compared with those 
of different coronaviruses belonging to the three existing groups. 
1 http: / / www. ncbi. nlm. nih.gov/entrez 
2 http: / /www • ncbi. nlm. nih.gov/gorf/gorf.html 
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Group 1 representatives included canine coronavirus (CCV) [Gen-
Bank accession no. AY342160], feline coronavirus (FIPV) [GenBank 
accession no. NC_007025], human coronavirus 229E (HCoV-229E) 
GenBank accession no. AF304460], porcine epidemic diarrhea virus 
(PEDV) [GenBank accession no. AF3535111, transmissible gas-
troenteritis virus (TGEV) [GenBank accession no. NC_002306], and 
human coronavirus NL63 (HCoV-NL63) [GenBank accession no. 
NC_005831]. Group 2 representatives included bovine coronavirus 
(BCV) [GenBank accession no. AF220295], human coronavirus 
OC43 (HCoV-OC43) [GenBank accession no. AY903460], mouse 
hepatitis virus (MHV) [GenBank accession no. AF201929], and rat 
coronavirus (RCV) [GenBank accession no. AF207551]. Group 3 
representatives included avian infectious bronchitis virus (AIBV) 
GenBank accession no. M95169] and turkey coronavirus (TCoV) 
GenBank accession no.AY342357]. Multiple sequence alignment 
and phylogenetic tree were generated by ClustalX (Ver. 1.83) soft-
ware wi th Gonnet protein comparison matrix. The phylogenetic 
tree was displayed by TreeView (Ver. 1.6.6) software. NetNGlyc 
1.0 server^ was used to predict potential N-gly cosy lat ion sites, and 
NetPhos 2.0 Server* was used to predict potential phosphorylation 
^NetGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/) is a neural network-based program 
for predicting potential N-glycosylation sites, that attempts to discriminate glycosylated se-
quons from non-glycosylated ones, 
'^NetPhos (http://www.cbs.dtu.dk/services/NetPhos/) is a neural network-based program 
for predicting potential phosphorylation sites at serine, threonine or tyrosine residues. 
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sites (Blom et al., 1999). The secondary structure and hydrophobic-
ity analyses on the sequence of the SARS-CoV S glycoprotein were 
performed with DNASIS MAX (Ver. 2.0) software (MiraiBio) based 
on Chou and Fasman algorithm and Hopp and Woods algorithm, 
respectively (Chou and Fasman, 1978; Hopp and Woods, 1981). 
2.1.2 Peptide design and molecular modeling 
Peptide sequences that correspond to the potential surface regions of 
the SARS-CoV S glycoprotein were designed based on the combined 
data from the above protein analyses (Table 2.1). 
T a b l e 2.1: A m i n o ac i d sequences of t h e six s y n t h e t i c p ep t i d e s " . 
D—•：“ Amino acid , . ,」 No. of Molecular , 
P印 t ide positions Ammo acid sequence amino acids mass, Da P' 
51 75-96 TFGNPVIPFKDGIYFAATEKSN 22 2416.6 6.74 
52 229-251 TNFRAILTAFSPAQDIWGTSAAA 23 2409.5 6.51 
53 573-593 ISPCSFGGVSVITPGTNASSE 21 2010.1 3.25 
54 1120-1140 YDPLQPELDSFKEELDKYFKN 21 2618.8 4.10 
55 788-820 LPDPLKPTKRSF 旧 DLLFNKVTLADAGFMKQYG 33 3754.2 9.53 
56 1002-1030 ASANLAATKMSECVLGQSKRVDFCGKGYH 29 3072.4 9.05 
“ P r o v i s i o n a l pa t en t app l i ca t i on number : 60/487,396 (F i l i ng date: J u l y 14, 2003). 
The three-dimensional structures of these peptides in the solvated 
state were simulated on an Insight I I molecular modeling platform 
(Accelrys) running on Silicon Graphics Octane 2 workstations. The 
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peptide models were constructed using the BIOPOLYMER module 
and then subjected to energy minimization and molecular dynam-
ics simulation using the DISCOVER module. A dielectric constant 
of 1.0 was used throughout the energy minimization and molecular 
dynamics simulation. The system was equilibrated at 300K for 100 
picoseconds (ps) during which time the potential energy of the sys-
tem reached a stable value. A time step of 1 femtosecond (fs) was 
used to integrate the equation of motion. The final conformation 
of the structure was obtained through 5000 iterations of steepest 
descent energy minimization. 
2.1.3 Solid phase peptide synthesis (SPPS) 
The six designed peptides were synthesized by a solid-phase tech-
nique wi th an Applied Biosystems 433A Peptide Synthesizer on 
amide resins using 7V"-9-fluorenylmethyloxycarbonyl (Fmoc) syn-
thesis (Figure 2.1) wi th 2-(IH-benzotriazol- 1-yl)-1,1,3,3-tetrameth-
yluronium hexafluorophosphate/l-hydroxybenzotriazole (HBTU / 
HOBt) coupling (Figure 2.2). 
too 
CH2-0 -C- | -
Figure 2.1: Fmoc-protecting group 
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Figure 2.2: A B I 433A Peptide Synthesizer 
Front View of the instrument, showing (1) keypad, (2) reaction vessel, (3) activator ves-
sel, (4) pusher block, (5) amino acid cartridges, (6) powerswitch, and (7) cartridge dis-
posal box. Reagents and solvents include (A ) piperidine, (B ) acetic anhydride in DMF , (C ) 
HBTU/HOBT, ( D ) methanol, (E) diisopropylethylamine (DIEA) in NMP, (F) dicyclohexyl-
carbodiimide (DCC) in NMP, ( G ) dichloromethane (DCM), and (H ) AT-methylpyrrolidone 
(NMP). 
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The amino (N) termini of peptides were acetylated on the resin 
with 150 g /L acetic anhydride in dimethyl formamide (DMF). The 
acetylated peptides were cleaved from the resins, and side-chain-
protecting groups were removed by cleavage solution containing 25 
g /L ethanedithiol (EDT) and 50 g/L thioanisole in trifluoroacetic 
acid (TFA). The peptides were then precipitated with cold diethyl 
ether, washed, and lyophilized. The cleaved peptides were purified 
with Agilent Technologies 1100 Series analytical and preparative 
HPLC systems using linear gradients formed from the solvent sys-
tems A (50 m L / L trifluoroacetic acid in H2O) and B (0.5 mL/L 
trifluoroacetic acid in acetonitrile (ACN)). The identities of puri-
fied peptides were confirmed by mass spectrometry on an Et tan^^ 
matrix-assisted laser desorption/ionization time-of-flight Pro Mass 
Spectrometer (Amersham Biosciences). 
2.1.4 Peptide conjugation 
Keyhole limpet hemocyanin (KLH) was dissolved in phosphate-
buffered saline (PBS) at pH 7.0 to a final concentration of 5 g/L. 
Approximately 1 mg of synthetic peptide was added to 1 mL of 
the K L H solution (i.e., approximately 200-300 mol peptides/mol 
of KLH). The mixture was sonicated in a water bath for 30 min; 5 
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mg of 7V-hydroxysuccinimide, 10 mg of l-ethyl-3-(3-dimethylamino-
propyl) carbodiimide hydrochloride were then added, and the mix-
ture was stirred at room temperature for 30 min. The mixture was 
loaded on a HiTrap^^ Desalting Column (Amersham Biosciences), 
and the eluate was collected as the KLH-conjugated peptide solu-
tion. 
2.1.5 Immunizat ion in rabbits and monkeys ^ 
Before the immunization of rabbits and monkeys, preimmune sera 
were collected and confirmed to be SARS-CoV negative by real-time 
quantitative RT-PCR as described previously (Ng et al., 2003). In 
the primary injection, 0.5 mL of complete Preund's adjuvant was 
added to 0.5 mL of purified antigen with a peptide concentration 
of 1 g /L (either conjugate-free peptide or KLH-conjugated peptide) 
and emulsified. Each rabbit (male New Zealand White; weight, 2-3 
kg) and monkey (male Macaca fascicularis^; weight, 2-3 kg) was 
immunized with 1 mL of emulsion by subcutaneous injection at five 
different sites on day 0 (Figure 2.3). 
The rabbits and monkeys were then boosted by subcutaneous 
injection of an emulsion containing 0.5 mL of incomplete Preund's 
^This part was conducted with the assistance of our collaborator Dr. Lin Shu-Guang's team 
in Research Center of Medical Sciences at Guangdong Provincial People's Hospital. 
6The monkey strain Macaca fascicularis was chosen in this study because it has been demon-
strated previously as a potent host of SARS-CoV that developed SARS symptoms after SARS-
CoV infection (Fouchier et al.、2003). 
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画 
Figure 2.3: Immunization in Macaca fascicularis. 
A : Monkey strain Macaca fascicularis was used for immunization to raise antibodies. 
B : A monkey was being injected with the peptide antigen emulsion. 
adjuvant and 0.5 mL of purified antigen on days 14 and 28. The 
first batch of rabbit and monkey antisera was collected 1 week after 
the second immunization. 
2.1.6 ELISA analysis 
Titrations of both the rabbit and monkey antisera against the corre-
sponding peptide or peptide conjugate were determined in duplicate 
by ELISA and the results were averaged. The purified antigens of 
the six synthetic peptides (either conjugate-free peptide or KLH-
conjugated peptide) were diluted to 10 mg/L in phosphate buffered 
saline (PBS); 100 /iL of the diluted antigen solution was added to 
the corresponding well of a 96-well microplate and incubated at 
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overnight. The wells were washed three times with 0.5 m L / L Tween 
20 in PBS; 100 JLIL of PBS containing 50 m L / L skim milk and 0.5 
m L / L Tween 20 was then added to each well and incubated at ST '^C 
for 2 h for blocking. The rabbit and monkey antisera against the 
synthetic peptides were diluted in a twofold series to 1:25, 1:50, 
1:100，1:200, 1:400，1:800, 1:1600, and 1:3200 in PBS containing 50 
m L / L skimmed milk and 0.5 m L / L Tween 20, and 100 JUL of diluted 
antiserum was added to each well. The plate was incubated at ST'^ C 
for 1 h. After plates were washed three times with PBS contain-
ing 0.5 m L / L Tween 20, bound antibody was measured by use of 
either alkaline phosphatase-conjugated goat anti-rabbit IgG or al-
kaline phosphatase-conjugated goat anti-monkey IgG (100 / iL/well 
of 1:500 dilution of IgG in PBS containing 50 m L / L skimmed milk 
and 0.5 m L / L Tween 20). After incubation at 37®C for 1 h and 
three washes wi th PBS containing 0.5 m L / L Tween 20, 100 /xL 
of developing solution (5 mg of p-nitrophenyl phosphate added to 
5 mL of substrate buffer containing 50 mL of diethanolamine, 50 
mg of MgCl2.H20，and 97.5 mg of NaNa； adjusted to pH 9.7 with 
NaOH and brought to 500 mL with Mi l l iQ H2O) was added to each 
well. Absorbance was monitored by a microplate reader at 415 nm. 
Both the rabbit and monkey preimmune sera were used as negative 
controls in this assay. 
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2.1.7 Immunofluorescent confocal microscopy 7 
The rabbit and monkey antisera against the synthetic peptides were 
diluted to 1:40-fold with PBS, and 10 /JL of each diluted serum was 
added to a well of the slide that was coated with S ARS- CoV-infected 
African green monkey kidney Vero cells and incubated at 37®C for 
1 h. The slide was washed three times with PBS and air dried. In 
each well of the slide, 10 /xL of the diluted conjugate (1:40) and 
Evan Blue (1:400) were added, and the slide was incubated at 37®C 
for 1 h. The slide was washed three times with PBS, air dried, 
and mounted. The mounted slide was observed with a confocal 
microscope. Noninfected African green monkey kidney Vero cells 
and the preimmune sera of both the rabbits and monkeys were used 
as negative controls in this assay. 
7This part was conducted with the assistance of our collaborator Dr. Chan Paul Kay-
Sheung's team in Department of Microbiology at The Chinese University of Hong Kong. 
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2.2 Synthetic peptide studies on SARS-CoV 3CLPr。 
2.2.1 Protein expression and purification 
The coding sequence of SARS-CoV used for cloning was 
based on the SARS-CoV BJOl strain complete genome sequence 
GenBank accession no. AY278488] downloaded from GenBank^. 
The construction of the pGEX-3CLP"» plasmid^ has been described 
previously (Yang et aL, 2003). The pGEX-3CLPr。plasmid was 
transformed into Escherichia coli {E. coli.) BL21(DE3) compe-
tent cells. Cultures were grown at 37®C in 250 mL Luria-Bertani 
(LB) medium containing ampicillin (100 mg/L) until the cell den-
sity reached an absorbance of 0.6 at 600 nm, and the culture was in-
duced with 0.1 mM isopropyl-l-thio-s-D-galactopyranoside (IPTG) 
at 25°C for 6 h. After induction, cells were harvested by centrifu-
gation at 4000 rpm for 20 min at 4。C. The bacterial pellet was 
resuspended in buffer A (pH 7.5) containing 10 mM Tris-HCl, 500 
mM NaCl, 1 mM dithiothreitol (DTT), 0.5 mM EDTA, and 0.2 
mM phenylmethylsulfonyl fluoride (PMSF). After cell lysis by son-
ication, the cell lysate was centrifuged at 20000 rpm for 45 min at 
4®C. Supernatant was loaded onto a Glutathione Sepharose™ 4B 
affinity column (Amersham Biosciences) equilibrated with buffer A. 
8 http: / /www. ncbi. nlm. nih.gov / entrez 
®The pGEX-3CLP*"° plasmid was provided by our collaborator Dr. Rao Zihe's team in 
Department of Biological Science and Biotechnology at Tsinghua University. 
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GST-tag was cleaved from the GST-3CLP^° fusion protein by on-
column proteolytic digestion with PreScission™ Protease (Amer-
sham Biosciences) overnight at 4。C. The SARS-CoV recom-
binant protein was eluted with buffer A, concentrated to 10 g/L by 
Microcon® Centrifugal Filter Devices (Millipore) and then stored 
at -20^C. The purity of protein samples were analyzed by discontinu-
ous sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) on a 12% gel as described (Laemmli, 1970)，followed by 
Coomassie blue staining. Protein concentrations were determined 
by the Bradford protein assay reagent (Bio-Rad). 
2.2.2 Solid phase peptide synthesis (SPPS) 
The sequence of peptide substrate used in this study was based on 
one of the SARS-CoV cleavage sites on the SARS-CoV BJOl 
polyprotein pplab (residues 3232-3247) (Table 2.2). 
The corresponding amino acid at the target position under inves-
tigation was deliberately substituted by a mixture of 20 standard 
amino acids in equal molar ratios during the solid-phase peptide 
synthesizing process, so as to generate a mixed pool of 20 different 
peptide substrates with single amino acid residue alteration at the 
target position. Each batch of the mixed peptide substrates was sub-
jected to in vitro enzymatic cleavage assay by recombinant SARS-
CoV 3CLPr° in a single reaction and then analyzed by MALDI-TOF 
CHAPTER 2. MATERIALS AND METHODS 42 




P9 P8 P7 P6 P5 P4 pa P1 PV P4_ P5' P6_ P7, 
PSO lb T S I T S A V L Q S G F R K M A 
PS02 T S I T S A V X A J F Q S G F R K M A 
PS03 T S I T S A X ^ Q ^ ' L Q S G F R K M A 
PS04 T S I T S X A O ^ V L Q S G F R K M A 
PS05 T S I T S 、 … R V L Q M G F R K M A 
PS06 T S I T S A V L Q ... S . . . . 霸 F R K M A 
PS07 T S I T S A V L Q S G X 雄 C R K M A 
“ T h e position (P) on the substrate is counted from the point of cleavage, i.e. P I is 
the position just before the cleavage site 丄，with P I , P2, . . . etc. located at N-terminal 
to the cleavage site; and PI ’ , P2', . . . etc. located at C-terminal to the cleavage site 
(Berger and Schechter, 1970). 
b The control peptide substrate is based on the amino acid sequence of one of the 
SARS-CoV 3CLPr° cleavage site on the SARS-CoV BJOl polyprotein pplab (residues 
3232-3247). 
c The corresponding amino acid at this position is substituted by a mixture of 20 
standard amino acids in equal molar ratios. 
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mass spectrometry to detect the susceptibility of each of the 20 pep-
tides to cleavage by SARS-CoV (Table 2.2). 
The biological significance of amino acid residues in the P2, P3, 
P4, PI，，P2' and P3，positions that are flanking the conserved Gin 
residue in P I position at the cleavage site were investigated one at a 
time using the 'cartridge replacement' solid-phase peptide synthesis 
strategy. Prior to peptide synthesis, the corresponding amino acid 
cartridge (Figure 2.4) at the target position under investigation was 
rcplaccd by a cartridge containing a mixture of 20 standard amino 
acids in equal molar ratio, such that a mixed pool of 20 synthetic 
peptides differing by a single amino acid residue was generated as 
the cnd-product after complete synthesis (Figure 2.5). 
B 麵 — C 尸 」 
SFmoc-Asp(OtBu)-Oi I ^ I ^ H * 
Peptide Synthesis Reagent ^ 
Part Number 400635 ^ 
属纖s ' t 'e rm I ^ H t i l 
Figure 2.4: An amino acid cartridge. 
A : Front view of an amino acid cartridge with label, showing this cartridge contains 
Asp. B : Left-side view showing the barcode, for identification of different amino acids 
by the peptide synthesizer. C : Right-side view with label (Asp). 
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F igu re 2.5: ’Ca r t r i dge rep lacement ’ sol id phase pep t i de synthesis 
Twenty kinds of amino acids are weighed and mixed in equal molar ratios. Here shows the (1) 
electronic balance, (2) twenty different amino acid powder in their corresponding bottles, (6) 
weighing paper, and (7) spatula. The mixture of amino acids is transferred to an empty amino 
acid cartridge (4), and a cap (5) is sealed to the mouth of cartridge with a cap crimper (3). 
Six sets of such peptide substrate pools together with the original 
peptide substrate were synthesized with this approach (Table 2.2) 
using standard protocol as described in section 2.1.3. 
2.2.3 Peptide cleavage assay 
The in vitro peptide cleavage assay was performed in a total reac-
tion volume of 25 /JL at pH 7.6, containing 1.5 /JM recombinant 
SARS-CoV 3CLPro, 9.5 mM peptide substrate, 20 mM Na2HP04, 
200 mM NaCl, 1 mM EDTA, and 1 mM DTT, with overnight in-
cubation at 25^C. Cleavage products were desalted by Reversed-
Phase Zip-Tip® (Millipore) and the corresponding peptide peaks 
were resolved by mass spectrometry on an E t tan™ MALDI-TOF 
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Pro Mass Spectrometer (Amersham Biosciences) (Figure 2.6). In-
ternal calibration was performed using the angiotensin I I I (Angl l l ) 
and adrenocorticotropic hormone (ACTH) standards. 
PELfekJ 
Figure 2.6: MALDI-TOF mass spectrometry. 
A : Desalted cleavage products were loaded on to the 96-well MALDI-TOF sample 
plate. B : Sample plate was inserted to the tray of MALDI-TOF mass spectrometer. 
C : Front view of the MALDI-TOF mass spectrometer. 
CHAPTER 2. MATERIALS AND METHODS 46 
2.2.4 Molecular docking 
All three-dimensional molecular modeling studies were performed 
on an Insight I I molecular modeling platform (Accelrys) running 
on Silicon Graphics Octane 2 workstations. The consistent valence 
forcefield (CVFF) was selected in all simulations. The X-ray crystal 
structure of the SARS-CoV (1UK4) was downloaded from 
the Protein Data Bank (PDB)io and used as a starting model The 
catalytic active site of chain A in the SARS-CoV structure 
without the bound CMK peptide was used in the study. Hydrogen 
atoms were added for the structure of SARS-CoV chain A 
using the BUILDER module. Then, the forcefield potentials and 
partial charges were assigned. 
The resulting structure was subsequently subjected to energy 
minimization using the DISCOVER module and was used as the 
initial structures for molecular docking. Since the proteolytic ac-
t iv i ty of SARS-CoV 3CLPro mainly relies on the active nucleophile 
Cysl45 and the acid-base catalyst His41, the region containing all 
residues (radius of 10.0 A) around this Cys-His dyad was selected as 
the target site and was used to set up as a grid with the DOCKING 
module. The nonbond energies of this region were precalculated 
on the grid. Different peptide substrates were then docked into 
the target site by manual docking using the DOCKING module. 
^°http://www.rcsb.org/pdb/ 
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The best docking position was based on the docking energy of the 
peptide/SARS-CoV complex. Thousand of orientations of 
peptides were searched by maneuvering it in the Cys-His dyad region 
of SARS-CoV 3CLPro manually until reaching the energy minimum. 
The resultant complex was subjected to energy minimization and 
molecular dynamics simulation using the DISCOVER module. A 
dielectric constant of 1.0 was used throughout the energy minimiza-
tion and molecular dynamics simulation. The system was equi-
librated at 300K for 100 picoseconds (ps) during which time the 
potential energy of the system reached a stable value. A time step 
of 1 femtosecond (fs) was used to integrate the equation of mo-
tion. The final conformation of the structure was obtained through 
5000 iterations of steepest descent energy minimization. Ultimately, 
the total docking energy between the peptide substrate and SARS-
CoV 3CLPr° in the energy minimized complex was calculated using 
the DOCKING module. The docking energy included the van der 
Waals and electrostatic energies, which were the components of the 
intermolecular energy. 
• End of chapter. 
Chapter 3 
Results 
3.1 Synthetic peptide studies on SARS-CoV S 
glycoprotein 
3.1.1 General features and structural analyses of the S 
glycoprotein 
The open reading frame (ORF) encoding for the spike (S) glycopro-
tein of SARS-CoV is 3768 nucleotide in length, comprising 12.67% 
of the total genome. The S glycoprotein is the largest structural vi-
ral protein in SARS-CoV and is composed of 1255 amino acids with 
an estimated molecular weight of 139.12 kDa; its isoelectric point 
(pi) is 5.48. There are 23 potential sites of N-linked glycosylation 
(Figure 3.1)，and 69 potential sites of phosphorylation, including 37 
serine, 15 threonine and 17 tyrosine residues (Figure 3.2). 
48 
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Figure 3.1: Predicted N-linked glycosylation sites on SARS-CoV S glycoprotein. 
Twenty-three N-glycosylation sites on the S glycoprotein of SARS-CoV 
were predicted. NetGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/) is a neural 
network-based program for predicting potential N-glycosylation sites, that attempts to 
discriminate glycosylated sequons from non-glycosylated ones. The graph illustrates 
predicted N-glycosylation sites across the protein sequence (x-axis: sequence position 
from N-terminal to C-terminal). A position with a potential (vertical green lines) cross-
ing the threshold (horizontal blue line at 0.5) is predicted to be glycosylated (as long 
as it occurs in the required sequon Asn-Xaa-Ser/Tlir without Proline at Xaa). 
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NetPhos 2.0： predicted phosphorylation sites in Sequence 
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Figure 3.2: Predicted phosphorylation sites on SARS-CoV S glycoprotein. 
Sixty-nine phosphorylation sites on the S glycoprotein of SARS-CoV, in-
cluding 37 serine, 15 threonine, and 17 tyrosine residues were predicted. 
NetPhos (http://www.cbs.cltu.dk/services/NetPhos/) is a neural network-based pro-
gram for predicting potential phosphorylation sites at serine, threonine or tyrosine 
residues in protein sequences. The graph illustrates predicted phosphoryaltion sites 
across the protein sequence (x-axis: sequence position from N-terminal to C-termiiial). 
A position with a potential (vertical lines) crossing the threshold (horizontal gray line 
at 0.5) is predicted to be phosphorylated (Bloni et al., 1999). 
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The secondary structure and the hydrophobicity of the SARS-
CoV S glycoprotein were predicted using DNASIS MAX (Ver. 2.0) 
software (Figure 3.3). 
A 1 100 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 700 8 0 0 900 1 ,000 1 ,100 l，255aa 
I 
L^ aipha-helix; Chou & faaman. Avem^ e=0.S7^ 94 k i, j 
B 1 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 700 8 0 0 9 0 0 1 ,000 1 ,100 l，255aa 
1 . I I . I I I . I . . I I I I I 
2 hydrophobicH^ : Hopp & Woods, Awrage=-0.2214ft7 
^ / L J j j u J ^ • J A J j J b i j J L j a l i L j U L J J U J J , a j lA J^ / ^ - J ^A l I 
Figure 3.3: Sequence analyses of SARS-CoV S glycoprotein. 
Secondary structure (A ) and hydrophobicity (B) predictions on SARS-CoV S glyco-
protein. 
The S glycoprotein of SARS-CoV demonstrates less than 50% 
identity of the previous identified S glycoproteins of other known 
coronavirus. Phylogenetic analysis using multiple sequence align-
ment of different coronavirus S glycoproteins suggested that SARS-
CoV defines a distinct fourth group of coronaviruses (Figure 3.4). 
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Figure 3.4: Phylogenetic relationships of SARS-CoV S glycoprotein to those of 
other coronaviruses. 
Unrooted neighbor-joining tree of S glycoproteins of 13 coronavirus species suggested 
that SARS-CoV defined a distinct fourth group of coronaviruses. Predicted amino acid 
sequence of SARS-CoV S glycoprotein was compared with those of different coron-
aviruses belonging to the three existing groups [Group 1: canine coronavirus (CCV) fe-
line coronavirus (FIPV), human coronavirus 229E (HCoV-229E), porcine epidemic diar-
rhea virus (PEDV), transmissible gastroenteritis virus (TGEV) and human coronavirus 
NL63 (NL63). Group 2: bovine coronavirus (BCV), human coronavirus OC43 (HCoV-
OC43), mouse hepatitis virus (MHV), and rat coronavirus (RCV). Group 3: avian 
infectious bronchitis virus (AIBV) and turkey coronavirus (TCoV).] using ClustalX 
(Ver. 1.83) program. Branch lengths are proportional to genetic divergence. (The 
scale bar indicates the number of amino acid substitutions per site.) 
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3.1.2 Peptides design and synthesis 
Because the crystal structure of the SARS-CoV S glycoprotein is not 
yet available, we designed six peptide sequences (SI, S2, S3, S4, S5, 
and S6) of twenty to thirty residues in length, which corresponded 
to the surface regions of SARS-CoV S glycoprotein based on the 
combined data of protein analyses. Most of them were expected to 
adopt a helix-loop motif and were hydrophilic; they were relatively 
widespread throughout the sequence of the SARS-CoV S glycopro-
tein. These six synthetic peptides were used as either conjugate-free 
peptide or KLH-conjugated peptide for immunization of rabbits and 
monkeys. The three-dimensional solution structures of these six 
synthetic peptides were simulated on an Insight I I molecular mod-
eling platform, which were expected to adopt the helix-loop motifs 
at their relatively stable energy states (Figure 3.5). 
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Figure 3.5: Predicted three-dimensional structures of the six synthetic peptides. 
A : SI peptide; B : S2 peptide; C : S3 peptide; D : S4 peptide; E: S5 peptide; and F: S6 
peptide. 
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3.1.3 EL ISA analysis and immunofluorescent confocal mi-
croscopy 
Prior to the immunization of rabbit and monkey, sera were collected 
and were confirmed to be SARS-CoV negative by real-time quanti-
tative RT-PCR. The first batch of the rabbit and monkey antisera 
against the six synthetic peptides was collected 1 week after the sec-
ond immunization, and was tested for antibody specificity against 
the corresponding peptide (either conjugate-free peptide or KLH-
conjugated peptide) by ELISA analysis. As shown in Figure 3.6 and 
Figure 3.7, all of these antisera were specific to their corresponding 
peptide antigens. Both the rabbit and monkey preimmune sera were 
used as negative controls in this assay. 
These rabbit and monkey antisera were tested for antibody speci-
ficity against SARS-CoV by immunofluorescent confocal microscopy. 
The antisera were incubated with African green monkey kidney Vero 
cells infected by SARS-CoV obtained from a SARS-CoV infected 
patient. Negative results (Figure 3.8) in immunofluorescent confo-
cal microscopy are indicated by a complete black microscopic field, 
whereas positive results (Figure 3.9) are indicated by the presence of 
green fluorescent signals. The results of immunofluorescent confocal 
microscopy are summarized in Table 3.1. 
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Figure 3.6: Titrat ion of rabbit serum samples diluted from 1:25 in a twofold series 
against constant antigen concentration of 10 mg/L. 
Anti-peptide antiserum is indicated by • with the corresponding preimmune serum, 
indicated by A , as negative control. Anti KLH-conjugated peptide antiserum is indi-
cated by • , and the corresponding preimmune serum is indicated by • as negative 
control. A : R_S1 antiserum ( • ) and R_S1_KLH antiserum ( • ) ; B : R_S2 antiserum 
( • ) and R-S2_KLH antiserum ( • ) ; :C: R_S3 antiserum ( • ) and R_S3_KLH antiserum 
( • ) ; D : R_S4 antiserum ( • ) and R_S4JKLH antiserum ( • ) ; E: R_S5 antiserum ( • ) and 
R_S5_KLH antiserum ( • ) ; F : R_S6 antiserum ( • ) and R_S6JKLH antiserum ( • ) ; G : 
R-MIX antiserum ( • ) and RJVIIX_KLH antiserum ( • ) . 
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Figure 3.7: Ti trat ion of monkey serum samples diluted from 1:25 in a twofold 
series against constant antigen concentration of 10 mg/L. 
Anti-peptide antiserum is indicated by • with the corresponding preimmune serum, 
indicated by A , as negative control. Anti KLH-conjugated peptide antiserum is indi-
cated by • ， a n d the corresponding preimmune serum is indicated by • as negative 
control. A : M_S1 antiserum ( • ) and M_S1_KLH antiserum ( • ) ; B : M_S2 antiserum 
( • ) and M_S2_KLH antiserum ( • ) ; :C: M_S3 antiserum ( • ) and M_S3_KLH antiserum 
( • ) ; D : M_S4 antiserum ( • ) and M_S4_KLH antiserum ( • ) ; E: M_S5 antiserum ( • ) 
and M_S5_KLH antiserum ( • ) ; F : M_S6 antiserum (A) and M_S6_KLH antiserum (•)； 
G : M_MIX antiserum ( • ) and M_MIX_KLH antiserum ( • ) . 
\ 
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Figure 3.8: Negative results in immunofluorescent confocal microscopy are indi-
cated by the absence of green fluorescent signals. 
A : negative control using rabbit R_S1 preimmune serum, observed under light micro-
scope (A-1) and confocal microscope (A-2). Similar results were observed in all other 
rabbit preimmune sera. B : negative control using monkey M ^ l preimmune serum, 
observed under light microscope (B-1) and confocal microscope (B-2). Similar results 
were observed in all other monkey preimmune sera. C : negative control using SARS 
patient serum on noninfected Vero cells, observed by light microscope C-1 and confocal 
microscope (C-2). D : negative result in confocal microscopy was shown for R_S1 anti-
serum, observed under light microscope (D-1) and confocal microscope (D-2). Similar 
results were observed in other antisera with negative results in confocal microscopy. 
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Figure 3.9: Positive results in immunofluorescent confocal microscopy are indi-
cated by the presence of green fluorescent signals in the cytoplasm of the African 
green monkey kidney Vero cells. 
A : positive control using SARS patient serum. Positive results in confocal microscopy 
were shown for the following rabbit and monkey antiserum samples: R_S2JKLH an-
tiserum (B); R_S5 antiserum (C) ; RJS5_KLH antiserum (D) ; R_S6_KLH antiserum 
(E); M_S3 antiserum (F); M_S6 antiserum (G) ; M_S6_KLH antiserum (H); MJVEIX 
antiserum (I); and M_MIX_KLH antiserum (J) . Each sample was observed under light 
microscope (1) and confocal microscope (2), respectively. 
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T a b l e 3.1: R e s u l t s of immuno f l u o r e scen t confoca l microscopy. 
Immunization in rabbits Immunization in monkeys 
Antigen used for Anticornm Result of confocal 打 R e s u l t of confocal 
immunization Antiserum microscopy Antiserum microscopy 
51 peptide R_S1 - M_S1 -
51-KLH conjugate R_S1_KLH - M_S1_KLH -
52 peptide R_S2 - M_S2 -
52-KLH conjugate R_S2一KLH + M_S2_KLH -
53 peptide R_S3 - M_S3 + 
53-KLH conjugate R_S3_KLH - M_S3_KLH -
54 peptide R_S4 - M_S4 -
54-KLH conjugate R_S4_KLH - M_S4_KLH -
55 peptide R_S5 + M_S5 -
55-KLH conjugate R_S5_KLH + M_S5_KLH -
56 peptide R_S6 - M_S6 + 
56-KLH conjugate R_S6_KLH + M_S6_KLH + 
Mix peptide® R—MIX - M_MIX + 
Mix-KLH conjugate^ R_MIX_KLH - M_MIX一KLH + 
a M i x pep t i de a nd M i x - K L H conjugate were prepared by m ix ing the six synthetic 
pept ides S I , S2, S3, S4, S5 and S6 in equal amounts . 
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For rabbit antisera, positive results were observed in samples 
R_S2_KLH，R_S5_KLH, and R_S6_KLH，which were elicited by the 
antigens: S2-KLH conjugate, S5-KLH conjugate and S6-KLH con-
jugate respectively. For monkey antisera, positive results were ob-
served in M_S3, M_S6, M_S6_KLH, M_MIX, and M_MIX_KLH, which 
were elicited by the antigens: S3 conjugate-free peptide, S6 conju-
gate free peptide, S6-KLH conjugate, M IX conjugate-free peptide 
and M I X - K L H conjugate, respectively. Non-infected African green 
monkey kidney Vero cells and the preimmune sera of both the rab-
bits and monkeys were used as negative controls in this assay (Figure 
3.8). The positive results indicated that most of the SARS-CoV was 
localized abundantly in the cytoplasm of the infected cells, which 
further confirmed the replication of SARS-CoV in the cytoplasm of 
animal host cells (Figure 3.9). 
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3.2 Synthetic peptide studies on SARS-CoV SCLPr。 
3.2.1 Substrate specificity of SARS-CoV 
In this study, we employed the MALDI-TOF mass spectrometric 
analysis in combination with the 'cartridge replacement' solid-phase 
peptide synthesis approach to examine the biological significance of 
amino acid residues in total six target positions at the SARS-CoV 
3CLPr° cleavage sites, including the P2, P3, P4 positions at the 
amino side of P I position; and the PI ' , P2', P3' positions at the 
carboxyl side of P I position (Table 2.2). 
Recombinant SARS-CoV was expressed in the E. coli. 
expression system, and the purity of the protein samples were ana-
lyzed by SDS-PAGE. As shown in Figure 3.10, the GST tag-removed 
SARS-CoV 3CLPr° recombinant protein was prepared with high pu-
rity, which was then subjected to the in vitro enzymatic cleavage 
assay wi th the peptide substrates. The cleavage results were moni-
tored by MALDI -TOF mass spectrometric analysis. 
The PSOl peptide, with its amino acid sequence based on one 
of the SARS-CoV 3CLPr° cleavage sites on the SARS-CoV BJOl 
polyprotein pplab (residues 3232-3247), was used as the positive 
control in the enzymatic cleavage assay to assess the activity of the 
recombinant SARS-CoV The original PSOl peptide peak 
with m/z value of 1739.03 resolved before the assay, was absent from 
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Figure 3.10: SDS-PAGE analysis of SARS-CoV 3CLP^° recombinant proteins. 
Lane 1: soluble fraction of E. coli. transformed with pGEX-3CLP*"° plasmid. Lane 2: 
purified GST-3CLP^° fusion protein after GST affinity chromatography (62.26 kDa). 
Lane 3: purified and concentrated SARS-CoV 3CLP^° recombinant protein without 
GST tag (33.85 kDa). All of the above samples were directly subjected to 12% SDS-
PAGE with the size control by the protein molecular weight marker (Lane M ) . 
the mass spectrum after the reaction (Figure 3.11), as it was cleaved 
by SARS-CoV 3CLP^®into smaller peptide fragments; which vali-
dated the enzymatic activity of the recombinant SARS-CoV 3CLPro 
that we prepared. The results of the in vitro enzymatic cleavage as-
say of the six batches of synthetic peptide substrates (PS02, PS03, 
PS04, PS05, PS06 and PS07) with amino acid substitutions in their 
corresponding target positions are summarized in Table 3.2. 
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Figure 3.11: Cleavage result of PSOl control peptide. 
PSOl control peptide peak (*) was resolved on the mass spectrum before the SARS-
CoV 3CLPro cleavage assay (A) ; and was absent from the mass spectrum after the 
assay (B) . 
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Table 3.2: Results of the in vitro peptide cleavage assay. 
” P e p t i d e T a r g e t ^ ~ C o r r e s p o n d i n g Amino acid substitution^ 
substrate Position amino acid Cleaved peptides Uncleaved peptid^i 
PS02 P2 [eu lie/Leu, Phe others。 
PS03 P3 Val others® Pro 
PS04 P4 Ala all' — 
PS05 P1_ Ser others® Pro, Asp, Glu 
PS06 P2_ Gly others® Pro, lle/Leu 
PS07 P ^ ^ ^ ™ 
° The position (P) on the substrate is counted from the point of cleavage, i.e. P I is 
the position just before the cleavage site 丄，with P I , P2, . . . etc. located at N-terminal 
to the cleavage site; and P I ' , P2', . . . etc. located at C-terminal to the cleavage site 
(Berger and Schechter, 1970). 
b The original amino acid residue in the position under investigation before the substi-
tution with 20 standard amino acids. 
e The identity of the amino acid in the particular peptide that substituted the residue 
at the position under investigation. 
d All peptides other than those in the opposite column were not cleaved by SARS-CoV 
3CLPro. 
e All peptides other than those in the opposite column were cleaved by SARS-CoV 
3CLPro. 
f All the 20 peptides were cleaved by SARS-CoV 3CLP^°. 
CHAPTER 3. RESULTS 66 
Before the enzymatic assay, the corresponding peaks of the 20 
peptides in each substrate pool were all resolved on the mass spec-
tra wi th their exact m/z values, which demonstrated the validity 
of solid-phase peptide synthesis using the cartridge replacement ap-
proach to generate a pool of 20 peptides with single amino acid 
difference at the target position. The results also demonstrated 
the capability of MALDI -TOF mass spectrometer to discriminate 
peptide species wi th single amino acid difference. 
P2, P3, and P4 positions at the amino side of the SARS-CoV 3CLPr° 
cleavage site 
For PS02 peptide substrates, only the original peptide {m/z value 
of 1739.04) and the peptide with Phe substitution for Leu in P2 po-
sition {m/z value of 1773.05) were cleaved, with their corresponding 
peptide peaks absence from the mass spectrum after the enzymatic 
assay; whereas all other peptides were not cleaved, with their cor-
responding peaks remained (Figure 3.12). For PS03 peptide sub-
strates, only the peptide with Pro substitution for Val in P3 posi-
t ion {m/z value of 1737.01) was not cleaved, with its corresponding 
peptide peak remained after the enzymatic assay; whereas all other 
peptides were cleaved (Figure 3.13). For PS04 peptide substrates 
wi th amino acid substitutions in P4 position, all the 20 peptides 
were cleaved completely, wi th their corresponding peaks absence 
from the mass spectrum after the enzymatic assay (Figure 3.14). 
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Figure 3.12: Cleavage result of PS02 peptide substrates. 
PS02 peptide substrates comprised a mixture of 20 different peptides with single amino 
acid alteration in P2 position (Leu) were subjected to SARS-CoV 3CLP^° cleavage 
assay. All 20 peptides were resolved on the mass spectrum before the assay (A); and 
only the peptide peaks corresponding to He/Leu (*) and Phe (**) substitutions in P2 
position were absent, whereas all other peaks remained after the assay (B). 
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Figure 3.13: Cleavage result of PS03 peptide substrates. 
PS03 peptide substrates comprised a mixture of 20 different peptides with single amino 
acid alteration in P3 position (Val) were subjected to SARS-CoV 3CLPr° cleavage assay. 
All 20 peptides were resolved on the mass spectrum before the assay (A) ; and only the 
peptide peak with Pro (*) substitution in P3 position remained after the assay (B). 
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Figure 3.14: Cleavage result of PS04 peptide substrates. 
PS04 peptide substrates comprised a mixture of 20 different peptides with single amino 
acid alteration in P4 position (Ala) were subjected to SARS-CoV 3CLPro cleavage 
assay. All 20 peptides were resolved on the mass spectrum before the assay (A); which 
were all absent from the mass spectrum after the assay (B). 
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P1', P2', and P3' positions at the carboxyl side of the SARS-CoV 
3CLPr° cleavage site 
For PS05 peptide substrates, only three peptides with Pro substitu-
tion (m/z value of 1749.05), Asp substitution (m/z value of 1767.05) 
and Glu substitution (m/z value of 1781.04) for Ser in PI ' posi-
tion respectively were not cleaved (Figure 3.15). For PS06 peptide 
substrates, only two peptides with Pro substitution (m/z value of 
1779.06) and Ile/Leu substitution (m/z value of 1795.09) for Gly in 
P2' position respectively were not cleaved (Figure 3.16). For PS07 
peptide substrates with amino acid substitutions in P3' position, all 
the 20 peptides were cleaved completely, with their corresponding 
peaks absence from the mass spectrum after the enzymatic assay 
(Figure 3.17). 
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Figure 3.15: Cleavage result of PS05 peptide substrates. 
PS05 peptide substrates comprised a mixture of 20 different peptides with single amino 
acid alteration in PI，position (Ser) were subjected to SARS-CoV cleavage 
assay. All 20 peptides were resolved on the mass spectrum before the assay (A); and 
the peptide peaks with Pro (*), Asp (**) and Glu (***) in P I ’ position remained 
after the assay (B). 
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Figure 3.16: Cleavage result of PS06 peptide substrates. 
PS06 peptide substrates comprised a mixture of 20 different peptides with single amino 
acid alteration in P2, position (Gly) were subjected to SARS-CoV 3CLP»"° cleavage 
assay. All 20 peptide peaks were resolved on the mass spectrum before the assay (A) ; 
and the peptide peaks with Pro (*) and Ile/Leu (**) in P2' position remained after 
the assay (B) . 
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Figure 3.17: Cleavage result of PS07 peptide substrates. 
PS07 peptide substrates comprised a mixture of 20 different peptides with single amino 
acid alteration in P3' position (Phe) were subjected to SARS-CoV 3CLP*"° cleavage 
assay. All 20 peptides were resolved on the mass spectrum before the assay (A); which 
were all absent from the mass spectrum after the assay (B). 
CHAPTER 3. RESULTS 74 
3.2.2 Molecular docking of SARS-CoV 3CLP^° and pep-
tide substrates 
Based on the mass spectrometry results from the in vitro enzymatic 
cleavage assay (Table 3.2)，four target positions including P2, P3, 
P r and P2' positions located at the SARS-CoV 3CLp^° cleavage 
sites were further analyzed by the Insight I I molecular modeling 
platform, and the molecular docking results are shown in Figures 
3.18 and 3.19. The control peptide, PSOl, was docked to the pre-
defined active site of SARS-CoV with the conserved Gin 
residue located at close proximity to Cysl45-His41 residues at the 
catalytic dyad of SARS-CoV (Figure 3.18); in which this 
energy data generated from energy minimization was used as the 
reference for comparing with the docking results using other peptide 
substrates. 
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Figure 3.18: Interaction between SARS-CoV 3CLP^° and PSOl control peptide 
as predicted by molecular docking. 
Overview (left) of the interaction between the SARS-CoV 3CLP^° (purple) and pep-
tide substrate PSOl (red); and the zoom-in view (right) of the conserved Gin residue 
(gray) in P I position at the cleavage site of PSOl control peptide being docked into the 
catalytic dyad of SARS-CoV 3CLP^° which is composed of the Cysl45 (orange) and 
His41 (yellow) residues. 
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F igure 3.19: Compa r i s on between the molecular models of different selected pep-
t i de substrates docked t o the act ive site of SARS-CoV 3CLPr。. 
The Cysl45 (orange) and His41 (yellow) residues in the catalytic dyad of SARS-CoV SCLP*"® 
(purp le ) and the conserved Gin residue (gray) in P I position at the cleavage site of the 
peptide substrate (red) were shown. A : PS02 peptide with Phe (green) in P2 position was 
in close proximity to the active site of SARS-CoV 3CLPro. Peptide substrates which were 
unfavorable for SARS-CoV SCLP*"" cleavage were deviated away from the active site of SARS-
CoV 3CLPro, which included: B : PS03 peptide with Pro (blue) in P3 position; C: PS05 peptide 
with Pro (blue) in P I , position; D : PS05 peptide with Asp (blue) in PI，position that was in 
close proximity to the acidic residues (brown) at the active site; E: PS05 peptide with Glu 
(blue) in P1' position that was in close proximity to the acidic residues (brown) at the active 
site; F : PS06 peptide with Pro (blue) in P2' position; G : PS06 peptide with lie (blue) in P2, 
position; H : PS06 peptide with Leu (blue) in P2' position. 
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For PS02 peptide with Phe substitution in P2 position, the en-
ergy level was similar to that of the PSOl control peptide, which fur-
ther confirmed the tolerance of Phe substitution at the P2 position 
at the cleavage site (Figure 3.19). On the other hand, the docking 
results for PS03 peptide with Pro substitution in P3 position, PS05 
peptides with Pro, Asp and Glu substitutions in PI ' position, and 
PS06 peptides with Pro, He, and Leu substitutions in P2' position, 
showed relatively high energy levels during docking studies when 
compared to the PSOl control, revealed the unfavorable cleavage 
reactions of these peptides by SARS-CoV 3CLP^° (Figure 3.19). 
• End of chapter. 
Chapter 4 
Discussion 
4.1 Synthetic peptide studies on SARS-CoV S 
glycoprotein 
4.1.1 Synthetic peptides elicited SARS-CoV specific an-
tibodies 
In this study, we designed a total of six peptide sequences, S1-S6 
(Table 2.1), that corresponded to the surface regions of SARS-CoV 
S glycoprotein based on the combined bioinformatics data from pro-
tein analyses. These six synthetic peptides were used to immunize 
both rabbits and monkeys. The results of immunofluorescent con-
focal microscopy indicated that four of the six synthetic peptides, 
i.e., S2, S3, S5, and S6, raised antibodies that could specifically rec-
ognize SARS-CoV, which suggested the efficacy of using synthetic 
peptides as antigens to elicit SARS-CoV specific immune responses 
(Figure 3.1). 
78 
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In a parallel study carried out at Tsinghua University using re-
combinant protein approaches, similar results were obtained. Pang's 
teami at Tsinghua University has generated a series of truncated 
recombinant protein analogs (SG3, analog of residues 73-882; SIO, 
analog of residues 730-1150; and S22, analog of residues 894-1192) 
of the SARS-CoV S glycoprotein to characterize the structural and 
functional properties of the S glycoprotein. Their immunoassays 
indicated that the SG3, SIO, and S22 analogs of the S glycoprotein 
were recognized by the IgG in sera from recovered SARS patients. 
Their SG3 analog is suggested to be the most specific immuno-
genic region on the S glycoprotein. Our work clearly demonstrated 
that the immunogenic region of their SG3 analog (residues 735-882) 
could be further delineated to residues 788-820, which corresponds 
to our S5 peptide (Table 2.1). In addition, our S6 peptide (residues 
1002-1030; Table 2.1) could be another minimum and significant 
immunogenic region of their SIO and S22 analogs of S glycoprotein. 
In addition, free S6 peptide is capable of inducing specific antibodies 
in monkeys. 
iPang H. 'Initial postgenomic studies of SARS coronavirus'. Presented at Advances in 
Protein Sciences, The Croucher Foundation Advanced Study Institute, December 15-20, 2003, 
Hong Kong. 
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4.1.2 Factors affecting the specificity and antigenicity of 
synthetic peptides 
There are several important factors contributing to the ability of 
the four synthetic peptides, i.e., S2, S3, S5，and S6, to elicit the 
production of SARS-CoV-specific antibodies. 
Strategies in peptide design 
Peptide design based on protein sequence is a critical and formidable 
task in this study. Choices of peptide sequences were deliberately 
targeted to the potential surface region of the SARS-CoV S glyco-
protein as predicted by in silico combined protein sequence analyses 
(Figure 3.3). Based on the assumption that the surface region of 
protein being exposed to the solvent is likely to be hydrophilic, 
we located the relatively hydrophilic stretches of the SARS-CoV S 
glycoprotein sequence using the Hopp and Woods algorithm (Hopp 
and Woods, 1981) as potential targets for peptide design. Secondary 
structure is another major consideration in the design of biologically 
active peptides. The three dimensional conformation assumed by 
the synthetic peptide in solvated state explicitly determines both 
the specificity and antigenicity of the peptide to elicit immune re-
sponses. The peptide backbone and polar side chains tend to ex-
hibit a driving force to be solvated, in which the length of 20 to 30 
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amino acid residues is enough for a peptide to adopt a stable heli-
cal structure in solution. Chou and Fasman algorithm was used to 
predict possible helical stretches of the SARS-CoV S glycoprotein 
sequence (Chou and Fasman, 1978). Most of the designed peptides 
were expected to adopt an a-helix motif to provide rigid and stable 
structures to enhance antigenicity (Figure 3.5). 
From bioinformatics analyses, it is noticed that the SARS-CoV 
S glycoprotein is heavily glycosylated and phosphorylated (Figures 
3.1 and 3.2). These regions in the SARS-CoV S glycoprotein se-
quence wi th possible posttranslational modifications are undesirable 
choices for peptide design, because the antigenicity at these regions 
is merely contributed by the non-specific sugar or phosphate moi-
eties rather than the more characteristic structural conformation 
alone. To generate peptide antigens with unique structural confor-
mations to elicit specific immune responses, we deliberately avoided 
these potentially glycosylated or phosphorylated regions in the pep-
tide design to ensure specificity and efficacy of our peptide antigens. 
To further enhance the antigenicity of these peptides, later work 
may include introducing several conformational constraints to these 
peptides to increase structural rigidity. Local conformation con-
straints can be introduced to restrict the mobility of single amino 
acid residue in the peptide, such as by replacing a hydrogen adja-
cent to a rotatable bond with a methyl group. Cyclization of linear 
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peptides can be performed by 'head to tail' formation of amide bond 
between the amino (N) and carboxyl (C) terminals, disulfide bridge 
formation between two Cys residues, or lactam bridge formation be-
tween Asp/Glu and Lys residues. Besides, from the in silico energy 
minimization studies of our peptides, the predicted loop size carried 
on the peptide may reflect its antigenicity; thus, the loop structures 
of these peptides could be further adjusted and strengthened to 
optimize the corresponding antigenicity (Figure 3.5). 
Mimicking the charge states in native protein 
Since our designed peptides are derived from the internal sequence 
I 
of SARS-CoV S glycoprotein, the presence of charges should be 
masked in order to mimic the charge states of the alpha amino and 
carboxyl groups in the native protein. Thus, we performed acetyla-
t ion at the amino (N) terminal and amidation at the carboxyl (C) 
terminal during solid-phase peptide synthesis, so that the peptides 
can resemble the surface region of the native S glycoprotein with a 
higher fidelity. 
Peptide conjugation to carrier protein 
Due to the relatively small sizes of synthetic peptides, these peptides 
alone may not be antigenic enough to elicit host immune response. 
Therefore, i t is suggested to conjugate these synthetic peptides to 
I 
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a suitable carrier protein to enhance both the antigenicity and sta-
bility. Keyhole limpet hemocyanin (KLH) was used as the carrier 
protein for conjugation to the synthetic peptides in this study. KLH 
is a large copper-containing protein that is isolated from the mol-
lusc Megathura crenulata with no homology with vertebrate pro-
teins. Other common carrier proteins include bovine serum albu-
min (BSA), rabbit serum albumin (RSA), and bovine thyroglobulin. 
Our results suggested that the KLH-conjugated peptides generally 
elicit better and more specific production of antibodies that recog-
nize SARS-CoV than conjugate-free peptides. 
4.1.3 Next step towards vaccine development 
On the basis of our studies, which demonstrated that four of the syn-
thetic peptides, i.e., S2, S3, S5, and S6, could elicit the production 
of SARS-CoV-specific antibodies, future experiments will be carried 
out to address the protective nature of these antibody responses in 
monkeys. This can be done by vaccinating noninfected monkeys 
with these synthetic peptides. After exposure of these vaccinated 
monkeys to live SARS-CoV, their health status could be monitored 
to determine the efficacy of these synthetic peptides as potential 
SARS vaccines. The monkey strain Macaca fascicularis would be a 
good choice for this animal test because this strain has previously 
been demonstrated as a potent host of SARS-CoV that developed 
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SARS symptoms after SARS-CoV infection (Fouchier et al” 2003). 
Because of the high infectiousness of SARS-CoV, a biosafety P3/P4 
level laboratory is required whenever performing any experiment 
using live SARS-CoV to prevent unpredictable outbreaks of SARS. 
4.1.4 A synthetic peptide-based approach 
The development of safe and effective vaccines is necessary for sus-
tained control of SARS. To date, vaccination against SARS is not 
available. Despite the efforts in SARS vaccine development are un-
derway globally, only the inactivated SARS-CoV vaccines are tested 
in clinical tr ial in China (He et al., 2004; Marshall and Enserink, 
2004; Zhou et al, 2005). Nonetheless, the major drawbacks of this 
inactivated SARS-CoV vaccines include the risk of incomplete inac-
t i vat ion of the vaccine virus, the induction of harmful immune hy-
peractivity and inflammatory responses after the immunization, and 
also the unpredictable laboratory accidents during vaccine prepara-
tion. In this study, we focused on using synthetic peptides for viral 
protein neutralization. Some of the major advantages of synthetic 
peptide vaccines are that they are relatively non-toxic and chem-
ically defined, and there would not be the presence of infectious 
agents or foreign protein, thus they demonstrate absolute biosafety 
in both manufacturing and use. Moreover, they can be synthesized 
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in high yields wi th high purity and they are stable at ambient tem-
perature. 
W i th the advance in peptide chemistry, a synthetic peptide-based 
approach could be a rapid initial step for providing useful informa-
tion for SARS research. Synthetic peptides have high flexibility in 
responding and confronting to newly emerging subtypes, in which 
new peptide antigens could be synthesized rapidly once the coding 
sequence of that particular subtype is known, without the need of 
generating the full-length protein. The results of synthetic peptide 
studies enable preliminary information about the possible antigenic 
determining sites on the native viral protein to be generated, which 
provide insights for generating a recombinant protein analog that 
could better mimic the conformation of the epitope regions. More-
over, the biophysical properties and binding kinetics of these syn-
thetic peptide candidates could be systematically characterized to 
allow elucidation of the structural and functional relationships of 
different SARS-CoV proteins. Our experimental data are informa-
tive and could advance the understanding of SARS. 
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4.2 Synthetic peptide studies on SARS-CoV 3CLP^° 
In this study, we have introduced a rapid and high throughput 
screening method to generate a comprehensive overview of the sub-
strate specificity preferences of SARS-CoV SCLP""®, via a combina-
tory strategy that employs MALDI-TOF mass spectrometry and 
'cartridge replacement' solid-phase peptide synthesis. Research on 
the substrate specificity preferences of SARS-CoV 3CLPr° is gaining 
increasing attention, owing to the biological significance of SARS-
CoV 3CLPro in the viral life cycle and the feasibility to design spe-
cific SARS-CoV 3CLPro inhibitors as potential anti-SARS drugs. 
I t has been demonstrated that SARS-CoV cleaves the 
coronavirus replicase polyproteins at no less than 11 conserved sites, 
involving the Leu-Gin [ sequence in P2 and P I positions at the 
cleavage site, respectively (Ziebuhr et al, 2000; Hegyi and Ziebuhr, 
2002; Anand et al, 2003). To further extend our knowledge on the 
substrate specificity of SARS-CoV we aimed to comprehen-
sively study the biological significance of amino acid residues in six 
selected positions (namely P2, P3, P4, PI ' , P2' and P3') flanking 
the conserved P I position at the SARS-CoV cleavage site 
by a rapid and high-throughput approach (Table 2.2). 
CHAPTER 4. DISCUSSION 87 
4.2.1 A comprehensive overview of the substrate speci-
ficity of SARS-CoV 3CLPr° 
P2 position 
In addition to the well-known conserved Gin residue in P I position 
at the SARS-CoV cleavage site, P2 position which is ex-
clusively occupied by Leu residue, also serves as another important 
determinant of substrate specificity. Since it is well known that Leu 
residue predominantly occupies the P2 position (Fan et al., 2004; 
Fan et al., 2005), the absent peak of Ile/Leu (*) after the assay (Fig-
ure 3.12) is suggested to be the control peptide having the original 
Leu in P2 position. The exact discrimination of the ambiguous lie 
and Leu residues yet requires further experiments involving the use 
of 2 different peptides in separate enzymatic cleavage assays. 
Our peptide cleavage results indicated that the peptide substrate 
with Phe replacement in P2 position was favorable for SARS-CoV 
3CLPrG cleavage (Figure 3.12), with similar energy level in molecular 
docking when compared to the positive control peptide with Leu in 
P2 position. Our results demonstrated consistency with other find-
ings (Fan et al., 2004; Fan et al., 2005), suggesting that P2 position 
serves as an important hydrophobic pocket for SARS-CoV 
specific binding; thus the peptide substrate with replacement of the 
original Leu with the more hydrophobic Phe in P2 position was still 
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susceptible to SARS-CoV SCLP""® cleavage. Other studies demon-
strated that SARS-CoV favorably tolerates Phe and Val 
substitutions, and to a lesser extent for Met substitution in the P2 
position (Fan et al, 2004; Fan et al, 2005); hence revealing the 
significance of the P2 hydrophobic pocket in the determination of 
SARS-CoV 3CLPre substrate specificity. 
P1' position 
Furthermore, the PI，position which is frequently occupied by Ser 
residue, also contributes to the substrate specificity of SARS-CoV 
3CLPro considerably. Our peptide cleavage results revealed PI，po-
sition is highly unfavorable to the substitution by Pro, Asp and Glu 
residues (Figure 3.15), which is consistent with the relatively high 
energy data generated by molecular docking studies. 
Our findings on the intolerance of Asp or Glu substitutions in P I ' 
position suggests that the acidic residues at the binding interface of 
the SARS-CoV 3CLPr° active site are probably in close proximity 
and sterically complementary to PT position of the substrate, lead-
ing to electrostatic repulsions between the negatively-charged acidic 
residues that hinder the substrate binding to SARS-CoV 
Our molecular docking results also demonstrated that the PI，posi-
t ion is proximal to the Glu47 and Asp48 residues at the SARS-CoV 
j i i 
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3QLpro active site (Figure 3.19), which further confirmed our in-
terpretations. Besides, the unfavorable substitution by Pro in PI， 
position could be accounted by the steric hindrance arising from its 
cyclic side chain (Figure 3.19), which obstructs the substrate bind-
ing to SARS-CoV Previous studies also demonstrated that 
small aliphatic residues such as Ser, Ala and Gly are favored in PI， 
position (Fan et al, 2004; Fan et a/., 2005). 
P3, P4，P2' and P3' positions 
Moreover, our results demonstrated the substrate specificity of SARS-
CoV 3CLPr° are less dependent on the P2' and P3 positions at the 
cleavage site. The substitutions of Pro, lie or Leu in the P2' position 
(Figure 3.16) and the substitution of Pro in the P3 position (Figure 
3.13) in the peptide substrates are unfavorable for the SARS-CoV 
3QLpro cleavage, in which these bulky Pro residue and /3-branching 
lie and Leu residues may cause steric hindrance to binding of SARS-
CoV 3CLPr° with its substrates (Figure 3.19). On the other hand, 
the peptide cleavage results showed that the P3' position (Figure 
3.17) and P4 position (Figure 3.14) have no effects on determining 
the substrate specificity preferences of SARS-CoV 
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4.2.2 Sequence comparison between SARS-CoV 3CLPro 
cleavage sites 
As discussed in section 4.2.1, our interpretations on the SARS-CoV 
3CLPro substrate specificity can be summarized as follows: (1) Gin 
residue is a necessary requirement in P I position at the conserved 
cleavage site; (2) P2 position is a hydrophobic pocket, that tolerates 
the replacement with hydrophobic amino acids; (3) PI，position is 
located proximal to the acidic residues at the SARS-CoV SCLP""® ac-
tive site, thus does not tolerate substitution of acidic amino acids; 
(4) Bulky Pro residue that leads to steric hindrance is not unfavor-
able for substitution in P3 and P2' positions, and /^-branching He 
and Leu residues are unfavorable for substitution in P2' position; 
(5) P4 and P3' positions exert no significant effects on determining 
the substrate specificity of SARS-CoV 3CLPr。. 
Since the results generated in this study were based on one of the 
SARS-CoV 3CLPre cleavage site on the SARS-CoV pplab polypro-
tein (residues 3232-3247) which may not necessarily represent all 
other ten cleavage sites, thus we attempt to compare the amino 
acid sequence of this studied cleavage site with the other ten cleav-
age sites to correlate their consensus of substrate specificity. The 
sequences of the 11 potential SARS-CoV cleavage sites on 
SARS-CoV BJOl poly protein pplab were predicted by NetCorona 
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NetCorona 1.8： Pred ic ted 3CL Proteinase Cleavage S i tes in Sequence 
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Figure 4.1: Predicted SARS-CoV 3CLp^° cleavage sites on SARS-CoV BJOl 
polyprotein pp lab . 
Eleven 3C-like protease cleavage sites were predicted on the SARS-CoV 
polyprotein pp lab . NetCorona (http://www.cbs.dtu.dk/services/NetCorona/) pre-
dicts coronavirus 3C-like protease cleavage sites using artificial neural networks on 
amino acid sequences. The graph illustrates predicted cleavage sites across the protein 
sequence (x-axis: sequence position from N-terminal to C-terminal). A position with a 
score (vertical blue lines) crossing the threshold (horizontal gray line at 0.5) is predicted 
to be possible cleavage sites (Kiemer et al., 2004). 
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Table 4.1: Amino acid sequences of the 11 cleavage sites of SARS-CoV 
Cleavage Amino acid position Sequence 
• a Protein product。 
site Start End P4 P3 P2 P1 P1' P2' P3' 
A V L " Q " " " S G F r ^ 
2 3543 3549 V T F Q G K F nsp3 
3 3833 3839 A T V Q S K M nsp4 
4 3916 3922 A T L Q A I A nsp5 
5 4114 4120 V K L Q N N E nsp6 
6 4227 4233 V R L Q A G N nsp7 
7 4366 4372 P L M Q S A D nsp9 
8 5298 5304 T V L Q A V G nsp10 
9 5899 5905 A T L Q A E N nsp11 
10 6426 6432 T R L Q S L E nsp12 
11 6772 6778 P K L Q A S Q nsp13 
a SARS-CoV 3CLP^° cleavage sites on SARS-CoV BJOl polyprotein pplab. 
b In this study, our peptide substrates are based on cleavage site 1 sequence, 
c After the proteolytic processing by SARS-CoV at the cleavage site, the cor-
responding non-structural protein (nsp) is yielded (Gao et al., 2003). 
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1.0 Server^ that is illustrated in Figure 4.1 (Kiemer et al., 2004), 
and sequence comparison is shown in Table 4.1 (Gao et al。2003). 
The conserved P I position is occupied by a Gin residue for all 
the 11 cleavage sites with no exceptions. The P2 position is pre-
dominantly occupied by the Leu residue, and occasionally being 
occupied by other hydrophobic amino acids, namely Phe, Val and 
Met for cleavage sites 2，3 and 7, respectively. In addition to Ser, 
other amino acids such as Gly, Ala, and Asn are found in PT po-
sition at the 11 cleavage sites, and none of these sites contains the 
cyclic Pro or acidic Asp and Glu in this position. The P3 position is 
commonly occupied by Val, Thr, Lys, or Arg residues, and no cyclic 
Pro is found in this position. Although all the cleavage sites do not 
contain the cyclic Pro in P2, position, /^-branching amino acids are 
found to occupy P2' position in two of the cleavage sites, i.e., lie 
and Leu for cleavage sites 4 and 10, respectively. In this study, we 
demonstrated that P2' position does not favor the substitution of 
lie and Leu for pplab cleavage site 1 (Table 4.1) owing to steric 
hindrance brought about by these /^-branching amino acids. The 
tolerance of lie or leu in P2' position at cleavage sites 4 and 10 can 
be accounted by the favorable overall structures of these 2 cleavage 
sites, are sufficient to mask the negative effects of the /^-branching 
amino acids in P2, position, hence, the SARS-CoV can still 
^NetCorona (http://www.cbs.dtu.dk/services/NetCorona/) predicts coronavirus 3C-like 
protease cleavage sites using artificial neural networks on amino acid sequences. 
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bind and cleave effectively at these sites without affected by the P2' 
position. Further experiments using the peptide substrates based 
on the sequence of these 2 cleavage sites can be conducted to com-
pare with the results in this study which employed the sequence of 
cleavage site 1. Different kinds of amino acids including the cyclic 
Pro are occupying the P3 and P4' position, suggesting that these 
2 positions are less important to determine the SARS-CoV 
substrate specificity. 
By comparing the sequences of the 11 SARS-CoV cleav-
age sites on the poly protein pplab (Table 4.1)，we demonstrated 
that our results on the sequence preference of cleavage site 1 is gen-
erally consistent with the other 10 cleavage sites, thus suggesting 
the feasibility in using this approach to generate a comprehensive 
overview of substrate specificity which can be generally applied to 
other cleavage sites. 
4.2.3 A rapid and high throughput approach to screen 
protease substrate specificity 
In contrast to providing quantitative measurements on the kinetic 
data of the interaction between SARS-CoV and the sub-
strates, the scope of our studies mainly focus on the description of 
a useful tool for rapid and comprehensive screen of substrate speci-
ficity for SARS-CoV which is also applicable to the studies 
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of other proteases. By combining the MALDI-TOF mass spectrom-
etry and synthetic peptide-based approaches, peptide cleavage stud-
ies on the defined equal molar mixture of a batch of twenty peptide 
substrates before and after the protease cleavage reaction could be 
performed simultaneous on a single mass spectrometric analysis. 
The resolution of MALDI-TOF mass spectrometer is good enough 
to resolve the twenty different peptides based on their m/z values, 
even for those peptides with 1-Da mass difference. Although one 
inevitable limitation of MALDI-TOF mass spectrometry is the in-
ability to distinguish between species of identical mass (i.e., He and 
Leu) or of almost the same mass (i.e., Gin and Lys); other amino 
acid residues with only 1-Da mass difference (e.g. Ile/Leu, Asn, 
Asp, Gin, Glu) can be clearly separated and resolved on the mass 
spectrum as side-by-side individual peaks as shown in Section 3.2.1. 
Our approach is advantageous over the traditional methods that are 
restricted to testing single peptide with defined condition each at 
a time, and the setup of a total of twenty identical experimental 
conditions for every analysis. After generating the comprehensive 
cleavage profile on the 20 peptides simultaneously in the first place 
based on our strategy, we can easily identify some of the important 
residues for pinpoint investigations. Hence, the next step can be 
proceed to the synthesis of target peptides in different batches if 
the separation of ambiguous residues (e.g. Ile/Leu, Gln/Lys) for 
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exact identification purpose is necessary. Certainly, if the cleav-
age result of each peptide (or a smaller number of mixed peptides 
in different batches) is to be analyzed separately, the resolution of 
the MALDI -TOF mass spectrometer instrument is not necessary to 
be as high as to distinguish between species with 1-Da mass dif-
ference. Nonetheless, the beauty of high resolution MALDI-TOF 
mass spectrometry is the ability to separate peaks with small mass 
difference (even as small as 1-Da), which enables us to generate a 
comprehensive cleavage profile on the 20 peptides rapidly, without 
the need of independent synthesis and analysis of each peptide one 
at a time. Besides, MALDI-TOF mass spectrometric analysis is tol-
erant to impurities; therefore, the reaction mixture can be analyzed 
directly after simple desalting procedure, which reduces the work-
load of subsequent downstream purifications of cleavage products 
prior to analysis. 
For the synthesis of peptide substrates, we deliberately applied 
the，cartridge replacement' strategy which was based on the flexi-
bi l i ty on modifying the solid-phase peptide synthesis (SPPS) pro-
cess, in which each amino acid cartridge can be filled with different 
contents of amino acids in defined ratios, to generate the desired 
combinations of mixed peptide substrates according to experimen-
tal needs. By the incorporation of MALDI-TOF mass spectrometric 
analysis and 'cartridge replacement' peptide synthesis approach, we 
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presented a useful tool that is widely applicable to studies that in-
volve the monitoring of protease cleavage activity, which include 
the rapid screening of potential protease inhibitors of other coro-
naviruses and the human immunodeficiency virus type 1 (HIV-1). 
On the basis of our studies, future experiments will be carried out 
to address the effectiveness of various synthetic peptide-based in-
hibitors in blocking the protease activity, with the ultimate aim of 
anti-SARS drug development. 
In this study, we have combined the sensitivity of MALDI-TOF 
mass spectrometry and the flexibility of solid-phase peptide syn-
thesis approach to generate SARS-CoV proteolytic cleavage 
data rapidly in a comprehensive manner. Our studies provide in-
sights on the full automation of these experimental procedures to 
meet the increasing demand of high-throughput and automated pro-
teomic studies. 
• End of chapter. 
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